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Abstract 
More than two decades ago it was realized that drug discovery and development strategies 
focusing exclusively on affinity enhancement and potency are unsuccessful. Instead, 
simultaneous optimization of pharmacodynamic and pharmacokinetic properties has been 
proposed and implemented. As a result, new assays for pharmacokinetic characterization were 
required and existing assays were modified to fulfill high-throughput requirements. These 
assays, typically used at early stages of drug discovery and development, were modified and 
employed during this doctoral thesis to determine pharmacokinetic parameters of 
carbohydrate mimetics. The project was termed PADMET platform, with PADMET standing 
for physicochemical properties, absorption, distribution, metabolism, elimination, and 
toxicity. The aims of the platform were on the one hand the elucidation of the 
pharmacokinetic behavior of carbohydrate mimetics and on the other hand the development of 
such compounds with improved drug-likeness. 
 
While building up the PADMET platform, the need for an inexpensive and uncomplicated 
pKa determination method became apparent. A methodology based on 
1H-NMR spectroscopy 
was chosen for this purpose and scope and limitations of this approach were explored. An 
excellent correlation to reference data was achieved.  
 
The components of the platform were used to characterize 93 carbohydrate mimetics 
regarding several pharmacokinetic parameters. The results were used in different projects of 
which two are discussed in detail in this thesis. First, one of the primary goals of the FimH 
antagonist project was the synthesis of orally available compounds with fast renal excretion. 
By the aid of various assays, molecules with a promising profile could be identified. Indeed, 
in vivo mouse studies confirmed the intended properties. The permeability values gathered 
during this project were correlated to calculated descriptors and to experimental lipophilicity 
values in order to identify the driving force of the permeation of carbohydrate mimetics. 
Calculated lipophilicity values as single descriptor proved to be superior to other descriptors 
and to combinations thereof.  
 
Second, during the MAG project compounds with maintained local concentrations in the 
cerebrospinal fluid were envisioned. Permeation through artificial blood-brain barrier and 
stability in artificial cerebrospinal fluid were thus determined. 
Abbreviations 
6 
Abbreviations 
aCSF artificial cerebrospinal fluid 
ADME absorption, distribution, metabolism, elimination  
AUC area under the curve 
BBB blood-brain barrier 
BBB-PAMPA blood-brain barrier parallel artificial membrane permeation assay 
Caco-2 cells Caucasian colon adenocarcinoma cells 
CE capillary electrophoresis 
CES carboxylesterase 
CFU colony forming units 
CHO cells Chinese hamster ovary cells 
ClAc 2-chloroactely 
CMC critical micelle concentration 
CNS central nervous system 
CRD carbohydrate recognition domain 
CSF cerebrospinal fluid 
CYP cytochrome P450 
D distribution coefficient 
DCE 1,2-dichloroethane 
DCM dichloromethane 
DMAP 4-dimethylamino-pyridine 
DMF N,N-dimethylformamide 
DMSO dimethyl sulfoxide 
DC-SIGN dendritic cell-specific intercellular adhesion molecule-3-grabbing non-
integrin 
DMEM Dulbecco’s Modified Eagle’s Medium 
DMSO dimethyl sulfoxide 
EPD electropotentiometric determination 
FAc 2-fluoroacetyl 
fb fraction bound 
FBS fetal bovine serum 
GADD45a growth arrest and DNA damage gene 
Gal galactose 
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GalNAc N-acetylglucosamine 
GFP green fluorescent protein 
GPE guinea pig erythrocytes 
HB hydrogen bond 
hERG human ether-a-go-go-related gene 
HPLC high-performance liquid chromatography 
IAM immobilized artificial membrane 
IC50 half maximal inhibitory concentration 
IgG immunoglobulin G 
iPrOH 2-propanol 
i.v. intravenous 
KD dissociation constant 
koff dissociation rate constant 
kon association rate constant 
LC-MS liquid chromatography-mass spectroscopy 
LDH lactate dehydrogenase 
MAG myelin-associated glycoprotein 
Man mannose 
MBP mannose-binding protein 
MDCK Madin-Darby canine kidney cells 
MeCN acetonitrile 
MOG myelin oligodendrocyte glycoprotein 
MS mass spectrometry or molecular sieve 
MTT 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide 
Neu5Ac N-acetylneuraminic acid 
NGFR nerve growth factor receptor 
NgR Nogo receptor 
NIS N-iodosuccinimide 
NMR nuclear magnetic resonance 
nosyl 2-nitrobenzylsulfonyl 
OAT organic anion transporter 
P partitioning coefficient 
PADMET physicochemical properties, absorption, distribution, metabolism, 
elimination, toxicity 
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PAMPA parallel artificial membrane permeation assay 
Papp apparent permeability 
PDB Protein Data Bank 
Pe effective permeation 
PEPT peptide transporter 
P-gp P-glycoprotein 
PK pharmacokinetics 
pKa negative common logarithm of the dissociation constant Ka 
PNS peripheral nervous system 
p.o. peroral 
PPB plasma protein binding 
PSA polar surface area 
p-Ts p-tolylsulfonyl 
QSAR quantitative structure-activity relationships 
QSPR quantitative structure-property relationships 
RhoA-ROCK Rho-associated, coiled coil-containing protein kinase 
RP reversed phase 
RTN4 reticulon 4 
S solubility 
SAR structure-activity relationships 
SASA solvent accessible surface area 
SGA spectral gradient analysis 
SGAG sulphated glycosaminoglycans 
sGF simulated gastric fluid 
sIF simulated intestinal fluid 
SPR structure-property relationships 
STD NMR saturation transfer difference NMR 
TEER transepithelial resistance 
TfOH trifluoroacetic acid 
THF tetrahydrofurane 
TMS trimethylsilyl 
trNOE transfer nuclear Overhauser enhancement 
UDPGT uridine diphosphate-glucuronosyltransferase 
UPEC uropathogenic E. coli 
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UTI urinary tract infection 
UV ultraviolet 
VCCLAB virtual computational chemistry laboratory 
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1 Introduction 
1.1 Pharmacokinetic characterization today 
Initially, the focus of the drug discovery and development process was primarily set on 
increasing affinity and establishing structure-activity relationships (SAR).1 However, it was 
realized that this strategy did not yield the necessary success, since many compounds that 
showed promising in vitro-results exhibited lacking in vivo-activity. When looking at the 
underlying cause, pharmacokinetic (PK) liabilities were suspected to be responsible for 39% 
of failures in phase I clinical trials.2 This high number, however, has often been 
misinterpreted, since the data set used in this study comprised a high percentage of antibiotics. 
With the revised data set only, 7 percent of failures were due to problematic PK behavior thus 
being only the fourth most important cause after lacking efficacy, animal toxicity, and adverse 
effects in man.3 Nevertheless, the stage was set for a new approach that focused not only on 
SAR but also on structure-properties relationships (SPR).4 As a consequence, a wealth of new 
experiments were implemented and combined with activity assays during early stages of drug 
discovery and development.5 Therefore, promising candidates for clinical testing could be 
identified that not only showed high activity at the target site but also reached it unaltered, 
within the intended time, and at sufficient concentrations. Today, besides various 
methodologies assessing absorption, distribution, metabolism, and excretion (ADME) 
properties, compounds are also characterized with respect to their physicochemical 
parameters which are often underlying descriptors for the other processes. Furthermore, 
toxicity is a key issue for successful drug discovery and development and is hence addressed 
already at early stages. In the following section, the most common parameters and the 
corresponding in vitro assays are briefly described. An excellent overview of these concepts 
can be gained by reading Kerns and Di6 who are presenting additional information concerning 
in silico and in vivo approaches.  
 
1.1.1 Physicochemical parameters 
pKa: The negative logartithm of the dissociation constant (pKa) of an acid or base describes at 
which pH a compound reaches its equilibrium between ionized and unionized form. For many 
ADME parameters this information is of crucial importance, since they can vary considerably 
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depending on which protonation state is predominant. Absorption, plasma protein binding, 
and excretion, amongst others, are known to be constrained by the pKa value.
6, 7  
The most common determination methods include spectral gradient analysis (SGA) based on 
changes of the UV-spectrum upon ionization,8 potentiometric titration assessing the pH-
change after adding acid or base,9 and capillary electrophoresis measuring the migration time 
through a capillary with different pH-buffers as eluent.10, 11 Furthermore, NMR-based 
approaches can be utilized.12-14  
 
logP/logD: Lipophilicity has been used for many years as an easily accessible surrogate 
marker for various biological processes including membrane permeation, plasma protein 
binding, and in vivo pharmacological and toxic effects. The field has been comprehensively 
summarized by Waring.15 Lipophilicity is commonly assessed as partitioning (logP) or 
distribution coefficient (logD). The first describes the ratio of the concentrations of the 
uncharged form of a compound in two immiscible solvents (usually octanol and water), the 
latter the ratio of summarized concentrations of uncharged and charged forms in the 
corresponding phases. logD thus depends on the pKa(s) of a compound. The gold standard for 
determination is the so-called shake-flask approach where the compound of interest is 
dissolved in buffer followed by the addition of octanol, then the mixture is shaken. After 
separation of the two phases, concentrations are assessed and the coefficient is calculated.16, 17 
Other commonly used determination methods include reversed-phase HPLC,18-21 capillary 
electrophoresis,22 and pH-metric approaches.23  
 
Solubility: Solubility is a key property, since low values might falsify assay results and oral 
availability might be seriously hampered.24, 25 Two different solubility definitions need to be 
distinguished, namely thermodynamic and kinetic solubility. The first is the solubility of a 
compound in buffered solution and is usually determined by the shake-flask procedure. The 
buffer is saturated with analyte and the solution is shaken. Then, the suspension is allowed to 
reach equilibrium between dissolved and precipitated compound. After filtration the 
concentration is determined.6, 26 Another option is the determination by potentiometric 
titration.27 Unlike the shake flask procedure, this approach requires an ionizable center in the 
molecule of interest. Thermodynamic solubility is mostly relevant for formulation and oral 
application studies. In contrast, kinetic solubility is measured starting from a DMSO stock 
solution. Besides the already mentioned pH-metric approach, that can also be applied for the 
determination of the kinetic solubility,27 three analytical methods are commonly used. First, 
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the UV method developed by Avdeef that measures the concentration of a compound after 
filtration against a single point standard.28 The compound addition as DMSO stock solution 
and concentration determination by UV-spectroscopy yields high-throughput compatibility. 
Second, nephelometric solubility determination can be used.29 Hereby, a serial dilution in 
buffer with constant DMSO concentration is performed and precipitation is detected by the 
scattering of a laser beam. Third, a turbidimetric approach has been described where constant 
amounts of DMSO stock solution are sequentially added to a stirred buffer solution in a 
cuvette.24 Upon precipitation, a diminished UV-transmission is observed. The results are of 
relevance for in vitro assays, since they are often based on compounds dissolved in DMSO. 
 
Critical micelle concentration (CMC): The CMC can be used for the prediction of ADME 
parameters (e.g., blood-brain barrier permeation)30-32 and toxicological effects (most 
prominently phospholipidosis)33 as well as for the explanation of unexpected assay results. In 
the latter case, when micelles are formed the actual free concentration is lower than 
anticipated leading to a right-shift of the concentration-effect curve. Furthermore, micelle 
formation is of importance for formulation development.34, 35 Determination methods include 
direct (via the surface tension)36-40 and indirect approaches. The latter are based on UV-41 or 
fluorescence-spectroscopy,42 NMR,43, 44 isothermal calorimetry (ITC),45-48 and capillary 
electrophoresis.49  
 
1.1.2 Absorption 
Oral availability is a highly desirable property for most indications, since it offers the 
possibility of applying a medication perorally, considered to be the most convenient treatment 
for patients. Besides sufficient solubility and metabolic stability, permeation through 
biological membranes is the most important prerequisite for oral availability.50 The 
assessment of this parameter already at early stages of drug discovery and development is thus 
of major interest and can be determined with three methods. 
 
Immobilized artificial membrane (IAM) HPLC: The principle of this method is the same 
as for HPLC-based techniques. A compound in the mobile phase is exposed to a stationary 
phase with bonded phospholipids and the retention time is compared to calibration 
compounds with known permeation properties.51-54 Even though the method is fast (when run 
with a gradient method),55 requires little material, and is insensitive to impurities, it is less 
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predictive than other methods. This is probably due to the fact that only physicochemical 
interactions with phospholipids can be studied and specific processes important for 
permeation through bilayers (molecular volume, polarity transitions) remain unvalued.6 
 
Parallel artificial membrane permeation assay (PAMPA): Ever since Kansy and 
coworkers introduced a methodology based on artificial membranes, permeation assessment 
has been greatly simplified and could be performed at high-throughput scale.56 In brief, filter 
supports of a sandwich-plate are impregnated with a phospholipid-solvent mixture. Then, 
buffer with the dissolved sample is placed in the lower (donor) while blank buffer is placed in 
the upper (acceptor) compartment. The two plates are then assembled and diffusion through 
the membrane is allowed to happen. Since its development, the assay has undergone various 
modifications with the aim to better mimic the physiological conditions and to speed up the 
procedure. For example, pH-gradients between the donor and acceptor compartment are 
applied, surfactant is added to the acceptor buffer in order to simulate plasma protein binding, 
and stirring plates are placed in the donor compartments in order to reduce the unstirred water 
layer.57-59 In general, PAMPA is a fast and relatively inexpensive tool for the assessment of 
membrane permeation by passive diffusion. However, neither active transport processes nor 
gastrointestinal metabolic degradation can be studied. 
 
Cell-based approaches: A more labor-intense and complex approach for the determination of 
permeation is based on cell-monolayers. These are cultivated on filter-support inlets of 6- to 
96-well plates. The flux of a compound in apical to basal direction or vice versa can be 
studied, giving indications on the expected in vivo behavior. Furthermore, active transport 
processes and to a limited extent also metabolic degradation can be studied.60 Commonly used 
cell lines are human colorectal adenocarcinoma cells (Caco-2)61-63 and Madin-Darby canine 
kidney cells (MDCK).64 Combined approaches using PAMPA and Caco-2 results have been 
described.65 
 
1.1.3 Distribution 
Distribution, in general assessed by the volume of distribution, is a parameter not easily 
accessible by in vitro testing. Often modeling based on various input parameters, such as 
lipophilicity and pKa, is required for prediction.
66, 67 Another highly important descriptor is 
plasma protein binding (PPB), since evasion into deeper compartments of the body, e.g., fatty 
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tissue or musculature, can only happen if a compound is not bound to blood components and 
can thus leave the circulation.68 Furthermore, PPB also strongly influences metabolism and 
excretion since in accordance with the “free drug” hypothesis only unbound drug is accessible 
to these processes.69, 70 Finally, high PPB is a risk factor for drug-drug interactions. 
 
Plasma protein binding (PPB): As illustrated above, PPB is important for the 
pharmacokinetic behavior of a compound and hence is determined by in vitro assays either 
prospectively or after suspicious in vivo experimental results. Various procedures have been 
established. Most commonly, PPB is determined by equilibrium dialysis. Briefly, a 
compartment containing plasma is separated by a semipermeable membrane from a buffer 
compartment. The compound of interest is added to the plasma compartment and the system 
is allowed to reach equilibrium. Then, the concentrations are determined in both 
compartments and the fraction bound to plasma proteins can be calculated. The approach has 
been miniaturized and is available on a 96-well scale.71, 72 Other procedures include plasmon 
surface resonance- (Biacore®) or nuclear magnetic resonance (NMR)-based approaches as 
well as ultrafiltration/ultracentrifugation, immobilized-protein HPLC-columns or 
microcalorimetry methods, amongst others.6 Concerns have been raised on whether PPB as 
single parameter is significant, since it has been shown that pharmacodynamic and 
pharmacokinetic behavior can also be influenced by binding kinetics, i.e., association and 
dissociation constants (kon and koff).
73-75 Therefore, these parameters together with PPB might 
provide a better understanding of a compound’s in vivo behavior than PPB alone. 
 
1.1.4 Metabolism 
Even though stability in various biological matrices, such as gastrointestinal fluids, plasma or 
cerebrospinal fluid, but also under assay conditions might be problematic, the main focus 
during the drug discovery and development process is often put on hepatic metabolism.6 This 
is mainly due to two factors. First, hepatic metabolic stability is a critical parameter, since the 
metabolites of a drug might be less active, inactive or even toxic. Characterization of 
metabolic pathways and the corresponding products is thus essential. Second, proneness to 
metabolic degradation bears the risk of causing drug-drug interactions and hence triggering 
adverse drug reactions.76 
In general, two phases of hepatic metabolism can be distinguished. Phase I metabolism is 
dependent on monooxigenases, so called cytochromes, that functionalize xenobiotics by 
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oxidation. Contrastingly, phase II metabolic reactions involve the conjugation with polar 
groups such as glucuronic acid, sulfate or glycine in order to facilitate renal excretion.77  
 
Determination of hepatic metabolic degradation: Different experimental approaches for the 
determination of metabolic degradation exist and are, ranked by raising complexity, based on 
liver microsomes, S9 fractions, hepatocyte cultures, and liver slices. Liver microsomes are 
prepared by differential centrifugation of homogenized liver tissue and contain membrane-
bound enzymes such as cytochromes P450 and UDP-glucuronosyltransferases (UDPGT). 
They are most commonly used for fast, preliminary hepatic stability screening of a large 
number of compounds.78, 79 If phase II metabolic degradation is of interest, either hepatocyte 
cytosol or S9 (supernatant of strained liver tissue homogenate) can be used.80 In contrast to 
cytosol, S9 also contains cytochromes P450 even though at lower concentration than in liver 
microsomes. Typically, these kinds of studies are performed at a later stage of drug discovery 
and development with selected compounds where phase II metabolism is suspected to play an 
important role. When the interplay of phase I and phase II metabolism together with cellular 
uptake by both active and passive mechanisms is of interest, hepatocytes are employed as test 
system.80, 81 They can be grown on supports or be used in suspension. The most complex 
system are high-precision rat liver slices which allow to study the passage through the liver 
including uptake by transporters, metabolic alteration, and biliary excretion.82 Both 
hepatocytes and liver slices represent sophisticated test systems and are therefore used at late 
stages of drug discovery and development for a complete metabolic characterization of 
selected compounds. 
Additionally to the approaches mentioned above, assays with recombinant human 
cytochromes are usually used for the elucidation of the contribution of one enzyme to total 
degradation.83 Furthermore, this allows a risk-assessment of drug-drug interactions and the 
planning of the corresponding clinical studies. In general, it is beneficial to have three or more 
enzymes involved in metabolic degradation, since this enables so-called metabolic switching, 
i.e., metabolic degradation by other enzymes in case one pathway is blocked.6 
 
1.1.5 Elimination 
A drug’s journey through the body ends with its elimination which is mainly dominated by 
two processes, namely hepatobiliar and renal excretion. While hydrophilic compounds and 
metabolites are usually excreted renally, lipophilic compounds that are not prone to metabolic 
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alterations are eliminated via the bile to the gastrointestinal tract.77 Both processes involve 
elimination from the blood stream. The difference, however, is that the uptake into 
hepatocytes can be due to active transport or passive permeation whereas excretion into the 
urinary tract system is first based on filtration in the glomeruli of the kidneys and only at later 
stages influenced by the processes mentioned above. The blood-urine barrier acts as selective 
filter for compounds with molecular weights below 60 kD that do not bear extensively 
negative charges.77, 84 Albumine and many other plasma proteins are thus barely filtered and 
remain in circulation while electrolytes, carbohydrates, and other small molecules, amongst 
them most xenobiotics, are readily filtered into the primary urine. From there reabsorption is 
possible by both transporter mediation and passive diffusion. In addition, active secretion can 
be a major component of overall renal clearance and can be identified by comparing a 
compound’s elimination to the creatinine clearance.77 Similarly, active transport processes are 
also of high importance for the extrusion of both unaltered xenobiotics and metabolites 
thereof from the hepatocytes into the bile. Due to the enormous importance active transport 
processes can play, various approaches to assess them have been developed.85 
 
Experimental procedures to study active transport: Four major determination methods are 
currently employed: the cell layer permeability method, the uptake method, the inverted 
vesicle assay, and the ATPase assay.  
The cell layer permeability method is based on a monolayer that is confluently grown on the 
filter of an inlet to a well plate. The permeation of a compound from the apical to the 
basolateral (PA>B) and from the basolateral to the apical (PB>A) compartment is assessed. If the 
transport from the apical to the basolteral compartment is bigger than in the other direction 
and the uptake ratio (PA>B / PB>A) is more or equal to 2, active uptake is probable. If on the 
other hand the transport from the basolateral to the apical compartment is bigger than in the 
other direction and the efflux ratio (PB>A / PA>B) is more or equal to 2, active efflux is 
probable.6 Besides Caco-2 and MDCK cells, transfected cell lines are often used for these 
experiments. 
The uptake method is based on cells that are transfected with specific transporters. These are 
exposed to a compound of interest, then uptake is stopped and the cells are washed. After 
lysis, the concentrations of both transfected and non-transfected (control) cells lysates are 
determined.86 The assay is rather simple and used as early screening tool. Common cell types 
include Chinese hamster ovary (CHO) cells and Xenopus oocytes.87 
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Inverted vesicles are based on the insertion of transporter genes into insect cells (Spodoptera 
frugiperda) which then produce vesicles containing these transporters. The vesicles are then 
inverted and expose their intracellular membrane to the outside. When they are added to 
solutions with compounds that are substrates for these efflux transporters, an intracellular 
accumulation results that can be detected after washing and lysis.88 
As last possibility, transporters of the ATP binding cassette family (e.g., P-gp) need energy in 
order to mediate substrate permeation through membranes. The required conversion of ATP 
to ADP and inorganic phosphate can be indirectly assessed by reacting the phosphate with 
ammonium molybdate. The intense color of this complex can be quantified by a UV-Vis plate 
reader.89 
 
1.1.6 Toxicity 
Toxicity is a tremendously important but complex area of drug discovery and development. 
Besides insufficient efficacy, toxicity is the most important cause for compound attrition in 
clinical trials and can lead to market withdrawal even after several years of successful 
application in therapy.90 Therefore, early in vitro studies to identify toxic structures are of 
crucial importance for the efficacy of a development program. The main focus lies on the 
determination of reactive metabolites and on off-target effects but also toxic effects due to 
agonism or antagonism at the therapeutic target have to be considered. At later stages of 
development, animal studies are unavoidable for a thorough elucidation of dose-toxicity 
relationships as well as for acute and chronic toxicity information. Based on these results, the 
doses for human phase I clinical trials can be determined. 
Due to spectacular market withdrawals caused by QT-prolongations and torsade des pointes-
arrhythmias in patients, a relatively new form of toxicity has been put into focus. 
Investigations revealed that these effects were caused by blocking specific cardiac potassium 
channels, so-called hERG channels, encoded by the human ether-a-go-go related gene. Even 
though the symptoms of hERG blocking are also depending on physiological and genetic 
factors91 and are in general a rare event (e.g., an incidence of arrhythmia in patients taking 
terfenadine of 1:50’000 was observed),92 it is of critical importance to avoid blocking due to 
the potentially fatal outcome.  
 
Early toxicity assays: Screening for hERG blocking has gained increasing importance. In 
general, either high throughput methods or in-depth, low throughput methods can be applied. 
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High-throughput experiments are performed with cells transfected with hERG and are based 
on membrane potential-sensitive dyes,93 radioactive ligand binding94 or rubidium efflux.95 
Furthermore, methods based on the patch-clamp approach that directly measure the membrane 
potential have been developed in high- and low-throughput applications.96 
Various screens for mutagenicity and genotoxicity have been developed and two types can be 
distinguished. These are on the one hand, assays looking at the direct influence of a test 
compound on DNA and chromosomes, e.g., in the micronucleus,97 chromosomal aberration98 
or comet assay99 and on the other hand, assays focusing on the mutation rate of different 
systems as indicator for mutagenicity, e.g., in the Ames test (bacteria),100 thymidine kinase 
mouse lymphoma cell101 (animal cells) or GADD45a-GFP102 (human cells) genotoxicity 
assay. 
In order to evaluate the cytotoxicity of a compound, several assays have been developed that 
assess normal cell function and membrane integrity. The MTT (3-(4,5-Dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide) human hepatotoxicity assay is based on the reduction of 
yellow-colored MTT to purple-colored formazan by mitochondria in healthy heaptocytes. 
Absorption at 550 nm of control cells and of cells exposed to a compound are compared, with 
lower absorption indicating cell toxicity.103 Another assay format exploits the uptake and 
accumulation of neutral red in lysosomes of healthy hepatocytes. Reduced accumulation 
suggests cytotoxic effects.104 Alternatively, the release of intracellular lactate dehydrogenase 
(LDH) due to membrane lysis of dead cells can be assessed. The principle is the LDH-
catalyzed production of formazan that can be quantified photospectroscopically.105 
Another important toxicological concern is the formation of reactive metabolites that would 
form adducts with biomolecules and consequently trigger cell damage or allergic reactions. 
Usually, reactive metabolites can be detected by adding glutathione to the same incubation 
mixtures as used for metabolic stability assays. With this method also the reactive site of the 
molecule can be determined.106 
 
1.1.7 Status quo and future perspectives 
As a result of these efforts, according to Kola and Landis, terminations of development caused 
by poor PK performance could be reduced.107 It needs to be noted, however, that other authors 
disagree with that view and could not find any amelioration, with toxicity and lack of efficacy 
as major problems.90 This latter study denominated pharmacokinetic liabilities to be 
responsible for 11% of development terminations while toxicity issues accounted for 33% of 
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terminations. Indeed, based on these numbers no major change is observable compared to 
Kennedy’s study3 which found pharmacokinetic reasons and toxicity in man and animals to be 
responsible for 7% and 33% of development terminations, respectively. It remains to be seen, 
to what extent toxicity and lack of efficacy are correlated with pharmacokinetic liabilities 
which might thus be the underlying cause.  
Therefore, further work is still required to ameliorate both the pharmacokinetic as well as 
toxicological evaluation. Kerns and Di consider prediction accuracy, lacking data for model 
development, and missing high-throughput methods for various areas (e.g., CYP induction, 
renal clearance, key toxic mechanisms) as critical fields with potential for improvement.1 
Furthermore, the need for development of fast, reliable, and inexpensive methods is 
highlighted. Balbach and Korn hint to the combination of tight schedules and little material 
synthesized in early drug discovery and development and conclude that fast assay procedures 
with low compound consumption are crucial prerequisites for successful projects.108 Van de 
Waterbeemd emphasizes the importance of exploiting existing databases for matched-pair 
analysis and as basis to reliably deduce structure-property relationships in order to make 
knowledge-based decisions.109 The same author together with Smith, Beaumont, and Walker 
stresses that attrition rates of drug candidates are still too high and they argue that better 
understanding of transporter-mediated processes will greatly contribute to better PK 
predictions. Furthermore, they state that better understanding of descriptors in combination 
with larger databases containing oral absorption and bioavailability results are required.110 
This is in line with the opinions of other authors that there is a great need for better prediction 
tools.109, 111 In addition, prediction of effectiveness needs to be improved further, since a lack 
thereof is the most important cause for the attrition of drug development projects.90 
 
 
1.2 Carbohydrates as drug targets 
1.2.1 Introduction to carbohydrates in biology and as drug target 
An excellent overview on carbohydrates as drug targets was written by Ernst and Magnani 
and basic information as well as many examples in this section have been taken from this 
review.112 In general, carbohydrates are the most abundant natural products. Every cell is 
coated by a layer of complex carbohydrates, so-called glycans, that form the glycocalyx.113 
Glycans include proteoglycans, glycoproteins, glycolipids, as well as 
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glycophosphatidylinositol-linked proteins and exhibit a broad diversity which originates from 
four factors. First, they are assembled from various monosaccharide building blocks which 
can, second, be linked in different positions. Third, every sugar can be linked severalfold 
leading to branched structures. Finally, the possibility of α- or β-linkage on the anomeric 
center further increases the structural complexity.  
The information of such highly complex surface structures is decoded by carbohydrate-
binding proteins that are involved in a wealth of important physiological and 
pathophysiological events. Currently, more than 80 such proteins are known and for many 
thereof binding specifity has been elucidated. Large screening programs with glycoarrays are 
performed to identify missing glycan-binding epitopes and together with existing information 
lead to new carbohydrate-related targets. This enables the synthesis of new chemical entities 
that mimic bioactive carbohydrates and thus form a new class of therapeutics. 
Even though carbohydrates are highly important for a plethora of biological processes, not 
many carbohydrates and carbohydrate-derived drugs have made their way into clinical 
application and a considerable number of pathophysiologically important carbohydrate-
protein interactions remain to be exploited therapeutically.112 Besides synthetic considerations 
(complex, multiple step-reactions; many sterocenters), pharmacokinetic liabilities might be 
responsible for this observation. The latter problem will be discussed in more depth in chapter 
1.3 of the introduction. 
Nevertheless, several carbohydrates or mimetics thereof have been successfully introduced to 
the market. Examples are found for various indications such as anticoagulation 
(fondaparinux,114 dalteparin,115 ardeparin,115 nardoparin,115 enoxaparin115), diabetes 
(voglibose,116 miglitol,117 acarbose118), epilepsy (topiramate),119 osteoarthritis (sodium 
hyaluronate),120 and Gaucher’s disease (miglustat).121 The most prominent examples, though, 
are probably the two drugs against influenza, zanamivir122 and oseltamivir.123 
In addition to these already marketed drugs, reams of new chemical entities are in preclinical 
or clinical evaluation. The main targets of these compounds are carbohydrate-binding proteins 
of the lectin family, since they are more homogeneous, better classified, and more selective 
than the sulphated glycosaminoglycans (SGAG) binding proteins.124, 125 The lectin family of 
vertebrates can be further divided into intracellular lectins (e.g., calnexin, L-type and P-type 
lectins) that are involved in glycoprotein processing and quality control by binding to core 
oligosaccharide structures and extracellular lectins (e.g., galectins, C-type, I-type, and R-type 
lectins) that recognize terminal carbohydrate epitopes of other cells and pathogens. The 
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extracellular lectins generally represent better accessible and more interesting molecular 
targets and are thus accounting for most carbohydrate drug discovery programs. 
 
1.2.2 C-type lectins as drug targets 
C-type lectins include two important research areas, namely antagonists against selectins and 
DC-Sign. The latter is discussed in the review paper mentioned at the beginning of this 
chapter112 and shall not be subject of this introduction. 
Selectins are probably the most intensely studied mammalian carbohydrate-binding proteins. 
Since their discovery in 1989,126-128 much progress has been made in the understanding of 
their function as adhesion-molecules.129 Three members of the family are known (E-, P-, and 
L-selectin) which all contain a Ca2+-dependent carbohydrate recognition domain (CRD) that 
recognizes a common carbohydrate epitope shared by sialyl Lea/x (sialyl Lewisa and sialyl 
Lewisx).130 Selectins represent an attractive therapeutic target in diseases where cell adhesion, 
extravasation of cells from the bloodstream or the migration of specific lymphocytes is 
important for the pathology. 
As an example, E- and P-selectins have been shown to mediate the acute adhesion and 
aggregation of leukocytes and erythrocytes during a vaso-occlusive crisis in a mouse model of 
sickle cell disease.131,132 Furthermore, aberrant extravasation of cells from the bloodstream is 
crucial for various inflammatory diseases (such as asthma, colitis, arthritis and psoriasis) as 
well as cancer. Tumor cells use the selectin pathway to extravasate out of the bloodstream in 
order to metastasize. A broad variety of solid tumors and adenocarcinomas, such as 
gastrointestinal,133 pancreatic,134 breast,135 lung,136 and prostate cancers,137 express high levels 
of sLex and sLea. Patients expressing these selectin ligands on gastric and colon tumor cells138 
have poorer chances of survival.139 Selectins and their ligands have also been reported to be 
important for the dissemination of hematological cancers140 and the homing of leukemic stem 
cells to microdomains within the bone marrow.141 Potent selectin antagonists therefore present 
new therapeutic opportunities for treating these diseases. Various compounds have entered 
clinical trials, amongst them bimosiamose against psoriasis and asthma (Phase IIa),142 GMI-
1070 for the treatment of acute sickle cell crisis (Phase II),143 and PSI-697 against 
atherothrombotic and venous thrombotic diseases (Phase I).144 
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1.2.3 I-type lectins as drug target 
The family of I-type lectins consists of carbohydrate-binding proteins in the immunoglobulin 
superfamily and include the Siglecs.145 The Siglecs are primarily expressed on leukocytes that 
mediate acquired and innate immune functions and act as cell signalling co-receptors. The 
variable cytoplasmic regulatory elements and diverse specificity for their sialoside ligands 
enable Siglecs to carry out unique roles at the cell surface. The best studied Siglecs are Siglec 
2, a regulatory protein that prevents the overactivation of the immune system and the 
development of autoimmune diseases, and MAG, a protein that blocks regeneration of the 
central nervous system (CNS) after injury.146 In contrast to the peripheral nervous system 
(PNS), the injured adult CNS is not capable of axon regeneration. Even though neurite 
outgrowth is possible in principal, it is prevented by inhibitor proteins expressed on residual 
myelin and on astrocytes that are recruited to the site of injury. Three major inhibitor proteins 
have been identified up to date: reticulon 4 (RTN4; also known as nogo A),147 myelin 
oligodendrocyte glycoprotein (MOG),148 and MAG.149 These three proteins activate the RTN4 
receptor, which then forms a complex with the nerve growth factor receptor (NGFR; also 
known as p75NTR). This leads to the activation of the RhoA–ROCK (Rho-associated, coiled 
coil-containing protein kinase) cascade resulting in growth cone collapse.150 MAG is further 
validated as therapeutic target by the high correlation between the degree of neurite outgrowth 
and the binding affinities of antagonists against this target, suggesting that potent glycan 
inhibitors of MAG can potentially enhance axon regeneration.151 Due to further refinements 
of the SAR profile, MAG antagonists that have improved affinities and, at least in some cases, 
remarkably simple structures have been identified.152-157 Unfortunately, owing to the use of 
different assay formats, it has been difficult to compare the reported affinities of these 
compounds for various ligands. 
 
1.2.4 Bacterial and viral lectins as drug targets 
Enteric, oral and respiratory bacteria require adhesion to the host's tissue for colonization and 
subsequent development of an infectious disease. This enables them to avoid clearance and 
killing by immune factors, bacteriolytic enzymes and antibiotics. Moreover, after adhesion 
bacteria are better able to acquire nutrients, further enhancing their ability to survive and 
infect the host. As a consequence, compounds that prevent the adhesion of pathogens to host 
tissues may offer a novel strategy to combat infectious diseases.158 Furthermore, because anti-
adhesive agents are not bactericidal, they are less likely to promote the propagation of 
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resistant strains than conventional bactericidal agents such as antibiotics. The strategy 
therefore seems promising for the reduction of the currently prevailing drug-resistance 
problem.159 Carbohydrate epitopes on the surface of host cells which are used by bacteria and 
viruses for colonization and infection represent the starting point of the search for 
glycomimetic entry inhibitors. However, that fact that most pathogens possess genes encoding 
several types of adhesins is a challenge for anti-adhesion therapy, since they may express 
different types, thus evading elimination by adhesion-blocking. Fortunately, glycomimetic 
antagonists that are designed to inhibit multiple adhesins are feasible to develop. 
Urinary tract infections (UTIs) are among the most prevalent inflammatory diseases that are 
caused by pathogens.160,161 The predominant pathogen in UTIs is uropathogenic Escherichia 
coli (UPEC), which causes more than 80% of all infections in otherwise healthy people 
(uncomplicated UTI). In healthy individuals, most uropathogens originate from the rectal 
microbiota and enter the normally sterile urinary bladder through the urethra, where they 
trigger the infection (cystitis). Once in the urinary tract, bacteria attach to the urinary tract 
epithelium through fimbrial adhesion molecules to avoid the host's defence mechanisms. 
Once bound, the bacteria are presumably internalized in an active process that is similar to 
phagocytosis.162 
Uncomplicated UTI can be effectively treated with oral antibiotics such as fluoroquinolones, 
cotrimoxazol or amoxicillin and clavanulate, depending on the susceptibility of the pathogen 
involved. However, recurrent infections and subsequent antibiotic exposure can result in the 
emergence of antimicrobial resistance, which often leads to treatment failure and reduces the 
range of therapeutic options. So, there is an urgent need for efficient, cost-effective and safe 
non-antibiotic therapy to prevent and treat UTIs without facilitating antimicrobial resistance. 
Inhibition of type 1 fimbriae-mediated bacterial attachment to the bladder epithelium is a 
promising approach to achieve this goal.163 Studies showed that α-mannosides are the primary 
bladder cell ligands for UPEC and that the attachment event requires the highly conserved 
FimH lectins, which are located at the tip of the bacterial fimbriae. A structure–function 
analysis showed that the residues of the FimH mannose binding pocket are invariant across 
200 UPEC strains.164 More than two decades ago, various oligomannosides165 and aromatic α-
mannosides166 that antagonize type 1 fimbriae-mediated bacterial adhesion were identified. 
Two approaches have been taken to improve their affinity: the rational design of ligands 
guided by information obtained from the crystal structure of FimH, and the multivalent 
presentation of the α-mannoside epitope. The crystal structure of the FimH receptor-binding 
domain was solved in 1999167 and the corresponding complex with oligomannoside-3 has 
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recently become available.168 Despite this detailed knowledge of the binding event, few 
attempts to translate this information into low-molecular-mass antagonists have been 
reported.166, 169, 170 The reference compound, methyl α-D-mannoside binds in the millimolar 
range,171 but the most potent monovalent antagonist reported so far binds with nanomolar 
affinity.170 Although monovalent and oligovalent antagonists with nanomolar affinity have 
been reported, there are no data available regarding their pharmacokinetic properties. 
However, for the treatment of UTI, oral bioavailability and fast renal excretion to reach the 
targets in the urinary tract are prerequisites for therapeutic success. 
Another popular research field in the area of bacterial lectins is the quest for new treatments 
against Pseudomonas aeruginosa. This topic is discussed in extensio in the review article 
mentioned at the beginning of this chapter112 and is not deepened further here.  
 
1.2.5 Future perspectives 
The knowledge and understanding of the involvement of carbohydrates has risen considerably 
over the past decades. Besides ongoing research for the identification of new carbohydrate-
related targets, major improvements concerning both activity and specificity could be 
achieved. Advancements in NMR spectroscopy172,173 and X-ray crystallography174 formed the 
basis for this development by providing structure-based information and understanding native 
interactions.175-178 Nevertheless, various shortcomings when working with carbohydrates and 
mimetics thereof prevail and need to be addressed better. Besides pharmacodynamic problems 
(e.g., enhancing binding affinity and simultaneously maintaining selectivity), pharmacokinetic 
liabilities are major drawbacks. To circumvent these problems, knowledge about negligible 
and replacable functional groups is crucial and will be benefited by improved analytical 
approaches enabling better access to structural information. In addition, early-ADMET assays 
are intended to address the problem of drug-likeness at an earlier stage and thus contribute 
significantly to successful drug discovery programs. 
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1.3 Carbohydrate antagonists and pharmacokinetics 
1.3.1 General considerations 
Unfortunately, not much information has been published concerning the pharmacokinetic 
behavior of carbohydrates and mimetics thereof. For example, since Lipinski’s seminal 
paper24 it is known that absorption from the gastrointestinal tract depends on lipophilicity, 
molecular weight, and number of hydrogen bond donors and acceptors. Various other 
publications found as well a significant dependence of permeation on these parameters and on 
polar surface area with low values generally being beneficial (except for logP).179-186 When 
looking at typical structural features of carbohydrates (such as rather high molecular weights, 
polarity, number of rotatable bonds, and number of hydrogen bond acceptors and donors) it 
becomes apparent that they contrast with the requirements for oral bioavailability. 
Furthermore, the low distribution coefficients (logD) as a result of the numerous hydroxy 
functions suggest low plasma protein binding, low volume of distribution, and low rates of 
metabolism.15 Together with the expected fast renal elimination,187 carbohydrates are prone to 
very short half-life times in plasma and would thus require frequent application. Furthermore, 
carbohydrates often show only high micromolar to even millimolar IC50 values. 
Consequently, without modifications to improve both the pharmacodynamic and the 
pharmacokinetic behavior carbohydrates are rather unattractive as drugs. 
Several strategies are used to address the above-mentioned problems. For the amelioration of 
permeation, omitting nonessential functional groups can prove useful. Moreover, a prodrug-
approach188 or the biosteric replacement of crucial groups189 could benefit oral availability. 
These modifications bear the additional advantage of enhancing the lipophilicity of the 
compounds and thus might enhance plasma protein binding, leading to longer plasma half-life 
times.70 On the other hand, metabolic alteration gets more probable with increasing 
lipophilicity and the property should thus be carefully balanced.15 
In addition to the above-mentioned considerations, active transport might be envisioned in 
case sufficiently high passive diffusion for oral absorption and arrival at the site of action is 
not achieved. There are numerous examples of marketed drugs for which active transportation 
is exploited, e.g., β-lactam antibiotics, heart glycosides, and fungicides. The possibility of 
active transportation can also be incorporated in rational design strategies. Transporters play 
furthermore an important role during the elimination process of carbohydrates concerning 
both active re-uptake and secretion. 
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The considerations discussed above found practical applications in the development of 
carbohydrates as exemplified in the next paragraph. 
 
1.3.2 Examples of successful pharmacokinetic amelioration of carbohydrates 
The most successful carbohydrate mimimetic currently on the market is oseltamivir. With a 
carbohydrate lead structure as starting point, lead likeness was reached by eliminating 
unrequired polar groups and metabolic soft spots. By the use of an ester prodrug-approach, an 
orally available neuraminidase-inhibitor was obtained.123 After absorption, the ester is cleaved 
liberating the active metabolite RO64-0802.190 With this strategy, an absolute bioavailability 
of the orally applied prodrug of 80% was achieved. Within 30 minutes the active metabolite is 
detectable in plasma and maximal concentrations are reached after 3 to 4 hours.191 
The antiviral drug valacyclovir is a good example for the successful exploitation of active 
transport processes. By adding the amino acid L-valine to the parent compound acyclovir, the 
oral availability could be increased fivefold due to active transport trough the gastrointestinal 
mucosa by the peptide transporters 1 and 2 (PEPT1 and PEPT2).192 As a result, the structural 
requirements for transportation by PEPT1 were elucidated and extensively studied.193 These 
efforts are expected to find broad application for various compounds with problematic 
bioavailability. 
Active transport can also be a disadvantage when the process is involved in excretion and 
elimination. Again, oseltamivir is a prominent example, since its active metabolite RO64-
0802 is actively excreted by organic anion transporters (OAT).194 Indeed, when oseltamivir is 
co-administered together with probenecid, a competitive inhibitor of OAT1, the serum half-
life of the active metabolite is prolonged.195 A better understanding of the role transporters 
play for pharmacokinetic processes will offer new opportunities or prevent failures due to 
inappropriate pharmacokinetic behavior. 
 
1.4 Aims of this thesis 
As exemplified in the previous chapter, not much is known about the pharmacokinetic 
behavior of carbohydrates and mimetics thereof. One aim of this thesis was therefore to 
provide additional information to better understand the factors influencing ADME processes 
and to expand the knowledge on the pharmacokinetic behavior of carbohydrates. Furthermore, 
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various assays were used to characterize carbohydrate mimetics with respect to their expected 
pharmacokinetic behavior.  
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2 Methods and assays 
2.1 The PADMET platform – an overview 
In order to analyze the pharmacokinetic behavior of the carbohydrate mimetics synthesized in 
the research group of Prof. B. Ernst at the University of Basel, various assays were built up 
and adapted to the requirements of this specific compound class. 
 
The first author was responsible for the building up of all assays, including their evaluation 
and adaptation to carbohydrate mimetics, and wrote the manuscript. 
 
This manuscript is in preparation for Bioorganic Medicinal Chemistry. 
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Abstract 
 
After researcher realized the importance of pharmacokinetic characterization for successful 
drug development and discovery, the focus was set on optimizing concomitantly 
pharmacodynamic and pharmacokinetic properties. Therefore, structure-activity relationships 
were complemented by structure-property relationships. For this purpose, properties of large 
data sets needed to be measured and consequently a wealth of new assays meeting high-
throughput requirements became necessary. As a result of these efforts, development failures 
due to pharmacokinetic liabilities could be reduced even though they remain responsible for 
11% of failures. 
 
Generally, it is striking that pharmacokinetic characterization seems to be restricted to 
company research and that only in isolated cases academic groups assess the according 
parameters. Instead, in silico tools or rules of thumb are frequently applied which are often 
developed based on known compound families. Therefore, their application to unknown, new 
chemical entities might be problematic. 
 
A possible explanation for the uncommonness of pharmacokinetic characterization in 
academic research might be the belief that the according assays are both complicated as well 
as expensive and that the efforts do not pay out. 
 
In this communication the feasibility of such assays in an academic environment is 
demonstrated. Furthermore, detailed experimental procedures with information about costs, 
required equipment and time consumption are given. Finally, the benefits for academic 
research projects are exemplified by the impact on three projects. 
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1. Introduction 
 
Towards the end of the last century, the importance of pharmacokinetic (PK) characterization 
during drug development has been recognized.1, 2 As a consequence, in vitro assays were used 
already at early stages of drug discovery for a reliable prediction of ADME properties of a 
given compound, i.e. its absorption, distribution, metabolism, and elimination.3, 4 Thus, the 
intestinal absorption of a new compound can be characterized by a number of 
physicochemical parameters, such as pKa,
5 solubility,6 and with limitations the distribution 
coefficient (logD).7-10 Additional evidence can be gained based on its permeation through an 
artificial membrane (parallel artificial membrane permeability assay , PAMPA)11 or on the 
cell level with monolayers of Caco-2 (colorectal adenocarcinoma cells)12 or MDCK cells 
(Madin-Darby canine kidney cells)13. Finally, a comparison of results obtained from PAMPA 
and Caco-2 cells allows the estimation of the contribution of active transport to the uptake 
mechanism.  
 
Convenient methods for the assessment of numerous additional pharmacokinetic parameters, 
including plasma protein binding14, 15 and metabolic stability (liver microsomes, cytochrome 
assays),16 are available. This led to an early engagement in the elucidation of structure-
property relationships (SPR), especially also quantitative structure-pharmacokinetic 
relationships (QSPR),17-19 in contrast to the exclusive focus on structure-activity relationships 
(SAR) that was prevalent previously. Responding to a growing interest, property-based lead 
optimization in order to ameliorate the pharmacokinetic properties of a lead came to the 
fore.20 Furthermore, ever since Lipinski et al. have shown in their seminal paper6 that also 
calculated descriptors such as molecular weight, ClogP, and the number of hydrogen donors 
and acceptors can be predictive for successful drug development, the importance of in silico 
prediction has been more and more recognized.21, 22 An excellent overview on assays and 
concepts applied in modern ADME optimization was recently published by Kerns and Li.9  
 
As a result of these efforts, late-stage failure in the drug discovery and development process 
due to PK liabilities has been reduced.23, 24 Nevertheless, problems related to the 
pharmacokinetic behavior of a compound remain responsible for on average 11% of 
development terminations during clinical phases I to III, a percentage that did not basically 
change over recent years.25 
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In general, it is striking that ADME characterization is almost exclusively restricted to 
company research (for examples see these references)26, 27 and that only in isolated cases 
medicinal chemistry groups in academia routinely assess pharmacokinetic parameters or 
profiles in vitro. For reaching drug-likeness, in silico methods or rules of thumb are applied. 
While these approaches might be useful for known compound families, they are not likely to 
be successful for new chemical entities, since computer-based prediction tools need to be 
trained for new compound series.28, 29 One explanation for the current status might be the 
misconception that the establishment of assays is both expensive and labor-intense and that 
these efforts can be avoided by more inexpensive in silico approaches. 
 
As our group is developing carbohydrate mimetics, prediction tools for PK properties most 
probably not developed or not trained with molecules from this compound class turned out to 
be unreliable. In addition, Since only a few examples of carbohydrate mimetic drugs were 
introduced to the market, only limited knowledge on ADME properties for this compound 
class exist.30 As a consequence of this lack of knowledge, we decided to build up a PADMET 
platform (physicochemical parameters, absorption, distribution, metabolism, elimination and 
toxicity) consisting of various assays for PK characterization of carbohydrate mimetics. 
 
In this communication, the feasibility of the project in an academic environment is 
demonstrated. All assays implemented in the PADMET platform are described with detailed 
experimental procedures. Finally, the benefits for various projects are demonstrated. 
 
 
2. Methods and assay description 
 
Protocols for different pharmacokinetic assays are presented to demonstrate their feasibility in 
an academic environment and to stimulate the buildup of PADMET platforms in other 
research groups. A short rationale for the interest in the according assay is given at the 
beginning of each section. At the end of every method description costs for consumables, time 
consumption, and required equipment are summarized (see also overview in Table 1). For 
most assays a LC-MS for concentration determinations (HPLC might also possible depending 
on the compound’s properties) and a temperature-controlled shaker are required. The 
methodologies do not rely on robotic equipment, even though many protocols could be 
adapted accordingly.  
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Table 1. Overview of time consumption and costs for different assays. Time consumption (including preparation 
of consumables and of experiment, excluding time for periods that do not require control, i.e. during shaking or 
concentration determination): + up to 3 hours, ++ 3 to 6 hours, +++ a whole day. Costs for consumables and 
special devices required for the experiments (excluding LC-MS, UV-spectrophotometer, NMR, shakers, 
centrifuge, incubator, and laminar flow): + inexpensive, ++ expensive but no major investment, +++ expensive 
and major investments required. 
Assay Time Costs 
logP/D (partition/distribution coefficient) ++ + 
pKa + + 
logS (solubility) + + 
PAMPA (parallel artificial membrane 
permeation assay) 
++ +++ 
Caco 2 cell-based assay +++ +++ 
PPB (plasma protein binding) ++ ++ 
Stability in the GIT + + 
Stability in the CNS + + 
 
 
Materials 
Dimethyl sulfoxide (DMSO), 1-octanol, pepsin, pancreatin, and Dulbecco’s Modified Eagle’s 
Medium (DMEM) high glucose were purchased from Sigma-Aldrich (Sigma-Aldrich, St. 
Louis MI, USA). PAMPA System Solution, GIT-0 Lipid Solution, and Acceptor Sink Buffer 
were ordered from pIon (pIon, Woburn MA, USA). L-glutamine-200 mM (100X) solution, 
MEM non-essential amino acid (MEM-NEAA) solution, fetal bovine serum (FBS), and 
DMEM without sodium pyruvate and phenol red were bought from Invitrogen (Invitrogen, 
Carlsbad CA, USA). Human plasma was bought from Biopredic (Biopredic, Rennes, France) 
and acetonitrile (MeCN) from Acros (Acros Organics, Geel, Belgium). The Caco-2 cells were 
kindly provided by Prof G. Imanidis, FHNW, Muttenz, and originated from the American 
Type Culture Collection (Rockville MD, USA). 
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logD7.4 determination  
Background: The distribution coefficient logD7.4 as a measure of lipophilicity enables 
predictions concerning various parameters (e.g., permeation, metabolism, plasma protein 
binding ) [10].  
Method: The in silico prediction tool ALOGPS31-33 was used to estimate the logP values of 
the compounds. Depending on these values, the compounds were classified into three 
categories: hydrophilic compounds (logP below zero), moderately lipophilic compounds 
(logP between zero and one) and lipophilic compounds (logP above one). For each category, 
two different ratios (volume of 1-octanol to volume of buffer) were defined as experimental 
parameters: 
 
Compound type logP Ratios (1-octanol: buffer) 
hydrophilic  < 0 30:140, 40:130 
moderately lipophilic 0 - 1 70:110, 110:70 
lipophilic > 1 3:180, 4:180 
 
Equal amounts of phosphate buffer (0.1 M, pH 7.4) and 1-octanol were mixed and shaken 
vigorously for 5 min to saturate the phases. The mixture was left until separation of the two 
phases occurred, and the buffer was retrieved. Stock solutions of the test compounds were 
diluted with buffer to a concentration of 1 µM. For each compound, six determinations, i.e., 
three determinations per 1-octanol:buffer ratio, were performed in different wells of a 96-well 
plate. The respective volumes of buffer containing analyte (1 µM) were pipetted to the wells 
and covered by saturated 1-octanol according to the chosen volume ratio. The plate was 
sealed with aluminium foil, shaken (1350 rpm, 25 °C, 2 h) on a Heidoph Titramax 1000 plate-
shaker (Heidolph Instruments GmbH & Co. KG, Schwabach, Germany) and centrifuged 
(2000 rpm, 25 °C, 5 min, 5804 R Eppendorf centrifuge, Hamburg, Germany). The aqueous 
phase was transferred to a 96-well plate for analysis by liquid chromatography-mass 
spectrometry (LC-MS).  
logD7.4 was calculated from the 1-octanol:buffer ratio (o:b), the initial concentration of the 
analyte in buffer (1 µM), and the concentration of the analyte in buffer (cB) with equilibration:  
! 
logD7.4 =
1µM " c
B
c
B
#
1
o :b
 
2 Methods and assays 
36 
The average of the three logD7.4 values per 1-octanol:buffer ratio was calculated. If the two 
mean values obtained for a compound did not differ by more than 0.1 unit, the results were 
accepted. 
Time: About 6 hours, possibility to determine 16 compounds in parallel in a 96-well plate. 
Costs: Inexpensive consumables (octanol, phosphate buffer, plate, sealing foil). 
Equipment: Plate shaker, pipettes (and optionally Hamilton syringe), centrifuge (ideally with 
insert for 96-well plate, otherwise transfer to tubes required), HPLC or LC-MS. 
 
pKa determination 
Background: pKa values are of crucial importance for many processes involved in a 
compounds passage through the body, including absorption, metabolism, distribution, 
excretion, and activity at the target.9 
Method: The pKa values were determined as described elsewhere.
34 Briefly, the pH of a 
sample solution is gradually changed and the chemical shift of protons adjacent to ionizable 
moieties is monitored. If the shift is plotted against pH a sigmoidal curve results whose 
inflection point confers to the pKa value.  
Time: About 3 hours are required if the pH needs to be gradually changed for one or two 
samples. If more compound is available and the NMR spectrometer has a automated sample 
handler series of 9 to ten samples can be prepared and measured over night. For this method 
only 1.5 hours are required. 
Costs: For the method described above the only requirements are D2O and NMR tubes and 
hence costs are very low 
Equipment: This determination method is simple and feasible in every chemistry lab, since it 
relies only on a pH-meter and NMR-access. 
 
Thermodynamic solubility determination 
Background: Solubility is a crucial parameter for drug discovery projects. Insufficient 
solubility will affect oral absorption,4 will lead to problems for i.v. applications and has the 
potential to negatively influence assay results.9 
Method: Microanalysis tubes (Labo-Tech J. Stofer LTS AG, Muttenz, Switzerland) were 
charged with 1 mg of solid substance and 250 µL of phosphate buffer (50 mM, pH 6.5). The 
samples were briefly shaken by hand, then sonicated for 15 min and vigorously shaken (600 
rpm, 25 °C, 2 h) on a Eppendorf Thermomixer comfort (Eppendorf, Hamburg, Germany). 
Afterwards, the samples were left undisturbed for 24 h. After measuring the pH, the saturated 
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solutions were filtered through a filtration plate (MultiScreen® HTS, Millipore, Billerica MA, 
USA) by centrifugation (1500 rpm, 25 °C, 3 min). Prior to concentration determination by 
LC-MS, the filtrates were diluted (1:1, 1:10 and 1:100 or, if the results were outside of the 
calibration range, 1:1000 and 1:10000). The calibration was based on six values ranging from 
0.1 to 10 µg/mL. Concentrations were determined by LC-MS. The upper limit for a reliable 
determination with this method is a maximum solubility of 3000 µg/ml. 
Time: About 3 hours, possibility to determine numerous compounds in parallel  
Costs: Inexpensive consumables (glass vials, 96-well plates, buffer components) except for 
the filtration plates (a package of ten suffices for 960 determinations, though). 
Equipment: Ultrasonic bath, shaker, pipettes, centrifuge (with insert for 96-well plate, 
otherwise different filtration device required), pH-meter, HPLC or LC-MS. 
 
Parallel artificial membrane permeation assay (PAMPA) 
Background: Oral availability is a desired property for drugs due to the ease of application. 
As a basis therefore, a compound needs to be able to permeate through biological membranes. 
A simple, high-throughput determination method to assess permeation through membranes is 
the PAMPA assay11 that uses a 96-well format with artificial membranes. 
Method: logPe was determined in a 96-well format with the PAMPA permeation assay. For 
each compound, measurements were performed at three pH values (5.0, 6.2, 7.4) in 
quadruplicates. For this purpose, 12 wells of a deep well plate, i.e., four wells per pH-value, 
were filled with 650 µL System Solution. Samples (150 µL) were withdrawn from each well 
to determine the blank spectra by UV-spectroscopy (SpectraMax 190, Molecular Devices, 
Silicon Valley Ca, USA). Then, analyte dissolved in DMSO was added to the remaining 
System Solution to yield 50 µM solutions. To exclude precipitation, the optical density was 
measured at 650 nm, with 0.01 being the threshold value. Solutions exceeding this threshold 
were filtrated. Afterwards, samples (150 µL) were withdrawn to determine the reference 
spectra. Further 200 µL were transferred to each well of the donor plate of the PAMPA 
sandwich (pIon, Woburn MA, USA, P/N 110 163). The filter membranes at the bottom of the 
acceptor plate were impregnated with 5 µL of GIT-0 Lipid Solution and 200 µL of Acceptor 
Sink Buffer were filled into each acceptor well. The sandwich was assembled, placed in the 
GutBoxTM, and left undisturbed for 16 h. Then, it was disassembled and samples (150 µL) 
were transferred from each donor and acceptor well to UV-plates. Quantification was 
performed by both UV-spectroscopy and LC-MS. logPe-values were calculated with the aid of 
the PAMPA Explorer Software (pIon, version 3.5). logPe values above -6.3 or membrane 
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retention of more than 80% were considered as threshold for oral availability (given no 
metabolic degradation occurs).35 For compounds with weak chromophores LC-MS detection 
is highly recommended. In this case, we made good experiences with diluting the acceptor 
medium with acetonitrile 1:1 (to break up the micelles) and to measure each reference well 
directly after the according donor well (less variability). Furthermore, both donor and 
reference samples need to be diluted not to exceed the linear concentration range of triple 
quadrupole-MS instruments. 
Time: For the protocol described above, about 6 hours distributed on two days (due to the 
overnight permeation period) are required. 7 compounds at three pH values or 21 compounds 
at one pH value in quadruplicates can be measured in one assay. Other protocols exist with 
shorter assay durations (i.e. 4 hours or 30 minutes) and the choice of the appropriate 
conditions depends on compound properties (mainly lipophilicity). 
Costs: Both expensive (buffers, PAMPA sandwiches, lipid mixture, UV-plates) and 
inexpensive (deep well plate) consumables are required. Since many transfer steps are needed, 
pipette tip consumption needs to be taken into account as cost factor. Furthermore, the 
PAMPA Explorer software needs to be purchased (major cost factor). Nevertheless, compared 
to cell-based assays PAMPA is easy to perform, requires little additional instruments and 
exhibits an excellent reproducibility of results. 
Equipment: 96-well UV-spectrophotometer, multichannel pipette, pipettes, pH-meter (for pH 
adjustment of buffers), LC-MS. Optionally, a GutBox® is required if the assay is performed 
under stirring conditions. 
 
Caco 2 cell assay 
Background: In contrast to the PAMPA, Caco-2 cell-based absorption assays12 also yield 
information about active transport processes and to a limited extent about metabolism. They 
are considered as surrogate cell-line for human small intestine cells and are thus used as 
model for gastrointestinal permeation. 
Method: The cells were cultivated in tissue culture flasks (BD Biosciences, Franklin Lakes 
NJ, USA) with DMEM high glucose medium, containing 1% L-glutamine solution, 1% 
MEM-NEAA solution, and 10% FBS. The cells were kept at 37 °C in humidified air, 
containing 8% CO2 and the medium was changed every second to third day. When 
approximately 90% confluence was reached, the cells were split in a 1:10 ratio and distributed 
to new tissue culture flasks. At passage numbers between 60 and 65, they were seeded at a 
density of 5.33 × 105 cells per well to Transwell® 6-well plates (Corning Inc., Corning NY, 
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USA) with 2.5 mL of culture medium in the basolateral compartment and 1.5 mL (days 1 to 
10) or 1.8 mL (from day 10 on) in the basolateral compartment. The medium was renewed on 
alternate days. Experiments were performed between days 19 and 21 post-seeding. DMEM 
without sodium pyruvate and phenol red was used as transport medium for experiments. 
Previous to the experiment, the integrity of the Caco-2 monolayers was evaluated by 
measuring the transepithelial resistance (TEER) in transport medium (37 °C) with an Endohm 
tissue resistance instrument (World Precision Instruments Inc., Sarasota FL, USA). Only 
wells with TEER values higher than 300 Ωcm2 were used. Experiments were performed in 
triplicates. Transport medium (10 µL) from the apical compartments of three wells were 
replaced by the same volume of compound stock solutions (10 mM). The Transwell® plate 
was then shaken (250 rpm) in the incubator. Samples (100 µL) were withdrawn after 5, 15, 
30, 60, and 120 min from the basolateral compartment and concentrations were analyzed by 
HPLC. Apparent permeability coefficients (Papp) were calculated according to the following 
equation 
! 
Papp =
dQ
dt
"
1
A " c0
 
where dQ/dt is the permeability rate, A the surface area of the monolayer, and c0 the initial  
concentration in the donor compartment.12 After the experiment, TEER values were assessed 
again for every well and results from wells with values below 300 Ωcm2 were discarded. 
Time: About one day is required for the assay preparation and its execution. It needs to be 
considered, however, that also cell cultivation requires considerable time (medium changes, 
splitting, freezing of backup samples).  
Costs: Cells and consumables (media, cell culture flasks, pipettes, Transwell® plates) are 
rather costly. Furthermore, the required infrastructure needed for work with cells (laminar 
flow bench, incubator) is a major cost factor. 
Equipment: Incubator, laminar flow bench, tissue resistance measurement instrument, plate 
shaker with temperature control (saturated atmosphere required, can be achieved by placing 
water container in shaker; alternatively, a normal shaker can be placed in the incubator), 
HPLC or LC-MS. Remark: Experience regarding the work with cell cultures is a precondition. 
 
Plasma protein binding (PPB) 
Background: Trainor nicely summarized the importance of plasma protein binding in 
arecently published review.14 In brief, it is assumed that only the unbound fraction of a 
compound can interact with a target, be metabolized, and be excreted (“free drug hypothesis”) 
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even though limitations may apply.9 Therefore, knowing the amount of unbound drug is of 
crucial importance. 
Method: The dialysis membranes (HTDialysis LCC, Gales Ferry, USA; MWCO 12-14 K) 
were prepared according to company instructions. The human plasma was centrifuged (5800 
rpm, 25 °C, 10 min), the pH of the centrifugate (without floating plasma lipids) was adjusted 
to 7.5, and analyte was added to yield 10 µM solutions. Equal volumes (150 µL) of phosphate 
buffer (0.1 M, pH 7.5) and analyte-containing plasma were transferred to the separated 
compartments of the assembled 96-well high throughput dialysis block (HTDialysis LCC, 
Gales Ferry, USA). Measurements were performed in triplicates. The plate was covered with 
a sealing film and incubated (5 h, 37 °C). Buffer and plasma compartment were processed 
separately. From the buffer compartments, 90 µL were withdrawn and 10 µL blank plasma 
were added. From the plasma compartments, 10 µL were withdrawn and 90 µL of blank 
buffer were added. After protein precipitation with 300 µL ice-cooled MeCN, the solutions 
were mixed, centrifuged (3600 rpm, 4 °C, 11 min), and 50 µL of the supernatant were 
retrieved. Analyte concentrations were determined by LC-MS. The fraction bound (fb) was 
calculated as follows: 
! 
f
b
=1"
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cp
 
where cb is the concentration in the buffer and cp the concentration in the plasma 
compartment. Values were accepted if the recovery of analyte was between 80 and 120%. 
Time: About 6 hours, possibility to determine 36 compounds in parallel (as triplicates) even 
though without robotic liquid handling 12 compounds are better feasible.  
Costs: The major cost factor for this assay is the purchase of plasma. Besides this, once the 
dialysis block has been purchased little additional costs will arise (for membranes and sealing 
films) since consumables are inexpensive. 
Equipment: Dialysis block, pipettes, multichannel pipette (not indispensable but comfortable 
for liquid handling in parallel), centrifuge, HPLC or LC-MS. 
 
Stability in simulated gastrointestinal fluids 
Background: Stability in the gastrointestinal tract is a precondition for absorption of a 
compound and can be a major obstacle in drug development.36 The according fluids can be 
simulated and a compound’s stability therein can be assessed. 
Method: Simulated gastric fluid (sGF) and simulated intestinal fluid (sIF) were prepared 
according to the United States Pharmacopeia (USP 28). sGF contained sodium chloride (200 
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mg), pepsin (320 mg) and 37% aq HCl (0.7 mL) in bidistilled water (100 mL). sIF consisted 
of monopotassium phosphate (680 mg), 0.2 M NaOH (7.7 mL), and pancreatin (1 g) in 
bidistilled water (100 mL). sIF was adjusted to pH 6 by adding 0.2 M NaOH. sGF and sIF 
were preheated (37 °C) and the compounds were added to yield 10 µM solutions. Incubations 
were performed on a Eppendorf Thermomixer comfort (500 rpm, 37 °C). Before starting the 
experiment (t = 0 min) and after an incubation time of 15, 30, 60, and 120 min samples (20 
µL) were withdrawn, precipitated with ice-cooled MeCN, and centrifuged (3600 rpm, 4 °C, 
10 min). The concentrations of analyte in the supernatant were analyzed by LC-MS. Stability 
was expressed as percentage remaining compound relative to the initial concentration. The 
concentrations of analyte in the supernatant were analyzed by HPLC or LC-MS. 
Time: About 3 hours, possibility to determine numerous compounds in parallel. 
Costs: Inexpensive consumables (simulated fluid components, tubes). 
Equipment: Temperature-controlled shaker, centrifuge, HPLC or LC-MS. 
 
Stability in aCSF (artificial cerebrospinal fluid) 
Background: For specific projects with compounds that are applied directly to the central 
nervous system or that are supposed to interact with targets therein, stability in cerebrospinal 
fluid might be a critical factor. Consequently, this parameter is of interest for such projects 
and can be assessed in artifcial cerebrospinal fluid. 
Method: Artificial cerebrospinal fluid was prepared according to published results with 
additionally 0.4% V/V human plasma.37, 38 The concentrations of electrolytes (in mmol/L) 
were the following: sodium 140, chlorine 125, hydrogen carbonate 22.5, potassium 2.9, 
calcium 1.15, magnesium 1, urea 4.16, and glucose 3.2. Solutions of analyte (100 µM) were 
prepared in this aCSF and incubated at 37 °C and 300 rpm on a Eppendorf Thermomixer 
comfort. 20 µL-samples were withdrawn after at the beginning of the experiment and after 30, 
60, 120, 180 minutes, and 24 hours and concentrations were analyzed by HPLC. 
Time: About 3 hours, possibility to determine numerous compounds in parallel  
Costs: Inexpensive consumables (simulated fluid components, tubes). 
Equipment: Temperature-controlled shaker, HPLC or LC-MS. 
 
LC-MS measurements 
Analyses were performed using a 1100/1200 Series HPLC System coupled to a 6410 Triple 
Quadrupole mass detector (Agilent Technologies, Inc., Santa Clara CA, USA) equipped with 
electrospray ionization. The system was controlled with the Agilent MassHunter Workstation 
2 Methods and assays 
42 
Data Acquisition software (version B.01.04). The column used was an Atlantis® T3 C18 
column (2.1 x 50 m) with a 3-µm particle size (Waters Corp., Milford MA, USA). The mobile 
phase consisted of two eluents: solvent A (H2O, containing 0.1% formic acid, v/v) and solvent 
B (acetonitrile, containing 0.1% formic acid, v/v), both delivered at 0.6 mL/min. The gradient 
was ramped from 95% A/5% B to 5% A/95% B over 1 min, and then hold at 5% A/95% B for 
0.1 min. The system was then brought back to 95% A/5% B, resulting in a total duration of 4 
min. MS parameters such as fragmentor voltage, collision energy, polarity were optimized 
individually for each drug, and the molecular ion was followed for each compound in the 
multiple reaction monitoring mode. The concentrations of the analytes were quantified by the 
Agilent Mass Hunter Quantitative Analysis software (version B.01.04).  
 
 
3. Application to current research projects 
 
In this section, the usefulness of the determination of pharmacokinetic properties shall be 
highlighted with a special focus on cross-validation by different assays. 
MAG project: In a recently published paper,39 nanomolar antagonists against the myelin-
associated glycoprotein (MAG) were presented. The question was raised whether the 
concentration of a locally applied antagonist can be expected to be maintained over time. An 
answer could be given by the aid of three assays, namely for the determination of log D7.3, 
BBB-PAMPA (blood-brain barrier parallel artificial membrane permeation assay), and 
stability in artificial cerebrospinal fluid. Even though low distribution coefficients at pH 7.3 
(log D7.3) in the range of -0.27 to 0.87 already suggested an evasion of antagonists from the 
cerebrospinal compartment by passive diffusion to be unlikely, this assumption was 
controlled by subjecting the compounds to a BBB-PAMPA (blood-brain barrier PAMPA). 
This assay is used to assess permeation through the blood-brain barrier and is basically a 
variation of the normal PAMPA with modifications in the lipid composition to better reflect 
the more lipophilic membrane of the blood-brain barrier. As expected, no permeation could be 
observed. Furthermore, the stability of the compounds in artificial cerebrospinal fluid was 
examined and no degradation over 24h occurred. In conclusion, both the high stability and the 
low potential for passive permeation make the maintenance of the local concentration for the 
synthesized compounds highly probable.  
FimH project: The aim of this project was to find an orally available, potent antibiotic agent 
with fast renal excretion to treat infections of the urinary tract. Indeed, compounds fulfilling 
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these requirements could be synthesized.40 The first generation showed desirable properties 
concerning renal excretion, i.e. low log D7.4 values and pKa values yielding ionized 
molecules.41 Nevertheless, these findings were contradictive to oral availability and indeed no 
permeation could be observed in the PAMPA. Therefore, a prodrug-approach was envisoned. 
The carboxy-moiety contained in the first-generation molecules was esterified to address the 
problem of insignificant membrane permeation by passive diffusion. As a consequence of this 
modification, PAMPA results were significantly ameliorated and in vivo oral bioavailability 
could be anticipated. However, in order to still profit of the desired properties of the first-
generation compounds rapid liberation of the active principle was a crucial precondition. 
Indeed, fast and specific ester-cleavage could be demonstrated. In addition, moderate in vitro-
plasma protein binding was observed which is in general a desirable finding if fast renal 
excretion is intended. Animal studies confirmed the properties expected after in vitro studies. 
In conclusion, the first orally available FimH antagonists could be achieved based on the 
systematic use of in vitro-ADME tools. The main remaining problem, namely the insufficient 
solubility of the compounds, is expected to negatively influence both absorption and 
applicability. Further publications will demonstrate the pharmacokinetic amelioration of the 
antagonists based on the findings of the first compound series.  
Selectine project: The above-mentioned assays were also applied to a third research area, 
namely to the selectine antagonist project. The most promising antagonists with the lowest 
IC50 values were characterized concerning their pharmacokinetic behavior. PAMPA, log D7.4, 
plasma protein binding, and critical micelle concentration (CMC) were determined. Especially 
the determination of the CMC was of critical importance, since micelle formation explained 
inconsistent assay results. 
General observations: Experimental determination often resulted in unexpected outcomes 
when compared to calculated data. This observation was especially valid for pKa and log D7.4 
determinations and can be attributed to the special compound class of carbohydrate mimetics 
that are most probably not used for the training of prediction tools. Given the inexpensive and 
fast determination protocols for both parameters presented above, it is suggested to apply 
these procedures also in other academic research institutions for a better insight into the 
expected pharmacokinetic behavior. 
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4. Summary and conclusions 
 
In this communication, the feasibility of pharmacokinetic compound characterization in an 
academic environment was demonstrated. An overview of various assays for the 
determination of physicochemical properties as well as the expected absorption, distribution, 
metabolism, and elimination behavior was given. Furthermore, detailed experimental 
procedures for every assay and information about the respective costs and required time were 
presented.  
 
In general, the different tools of the PADMET platform proved to be useful and stimulating 
for three different research projects. The predicted behavior could be confirmed in one case 
with animal studies. Differences between calculated and experimentally determined values 
were frequently observed. In conclusion, it seems thus reasonable to use various assays in 
order to identify the most promising compound with both satisfactory pharmacodynamic and 
pharmacokinetic behavior for in vivo testing.  
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2.2 One method in detail: pKa determination by NMR 
 
A detailed method description for the pKa determination by NMR is presented in this chapter. 
Even though the methodology is not new, it is the first time that its scope and limitations were 
explored. The numerous advantages of this approach make it a valid tool for pKa 
determination in an academic environment. 
 
The first author was responsible for the building up of the assay, including its evaluation, and 
he performed or supervised all measurements and evaluations. Furthermore, he wrote the 
manuscript. 
 
This manuscript is in preparation for ChemMedChem. 
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Abstract 
 
pKa values of acids and bases have an essential impact on organic synthesis, medicinal 
chemistry as well as material and food sciences. Especially in drug discovery and 
development, pKa values are of upmost importance for the prediction of pharmacokinetic and 
pharmacodynamic properties, for example permeation through biological barriers, interactions 
with targets or induction of side effects 
 
To date, different methods for the determination of pKas are available, including 
potentiometric, UV-spectroscopic, and capillary electrophoresis techniques. An additional 
option is provided by nuclear magnetic resonance (NMR) spectroscopy. The underlying 
principle is the alteration of chemical shifts of magnetic nuclei (13C and 1H) depending on the 
protonation state of an adjacent acidic or basic site. When these chemical shifts are plotted 
against the pH, the inflection point of the resulting sigmoidal curve defines the pKa.  
 
Although pKa determinations by 
1H-NMR spectroscopy are reported for numerous, but mostly 
isolated cases, the potential of this approach is not yet fully evaluated. We therefore revisited 
this method with a diverse set of test compounds covering a broad range of pKa values (pKa 1 
to 14). The much higher natural abundance and gyromagnetic ratio of 1H compared to 13C 
leads to higher sensitivity and therefore a reduction of sample consumption and measuring 
time. A comparison with values obtained by an UV spectroscopic method and with reference 
values from electropotentiometric determination revealed an excellent correlation and 
confirmed the reliability and utility of the 1H-NMR approach. Furthermore, a comparison with 
computed results showed that the NMR-based approach yielded pKa values with a lower 
maximal deviation. Overall, a fast access to pKa values can prove to be extremely beneficial in 
organic synthesis as well as in medicinal chemistry.  
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1. Introduction 
 
pKa values of acids and bases have an essential impact on organic synthesis, medicinal 
chemistry as well as material and food sciences. Especially in drug discovery and 
development, pKa values are of upmost importance for the prediction of pharmacokinetic and 
pharmacodynamic properties, for example permeation through biological barriers, interactions 
with targets or induction of side effects.1 It is therefore indispensable to have access to this 
parameter at an early stage of medicinal chemistry program. 
 
For the determination of pKa values, various experimental approaches based on different 
analytical methods are commonly used. First, protonation and deprotonation can be followed 
by spectrophotometric methods.2 This approach, the so-called spectral gradient analysis 
(SGA), offers the advantage of being highly compatible with automation and therefore 
medium to high-throughput applications. Moreover, pKas at low and high pHs with 
overlapping values, and with an appropriate co-solvent for hardly soluble compounds, can be 
determined. However, the spectrophotometric approach relies on chromophores in proximity 
to the ionizable centers. Furthermore, depending on the spectroscopic properties, sample 
concentrations larger than the typically used 50 µM, might be necessary. Finally, sample 
impurities can lead to distortions of the results.  
 
An alternative approach is based on potentiometric measurements, also called the pH-metric 
approach, where the pH-change caused by the addition of acid or base enables the 
determination of pKa values.
3 The advantages are identical to those of the UV-spectroscopic 
determination. A further benefit is that chromophores are no longer required. However, the 
impurities remain critical and the method is rather slow. Nevertheless, the pH-metric method 
is considered the gold standard.4  
 
With capillary electrophoresis (CE), a third method for pKa determination is available.
5-9 As 
the migration time through a capillary depends on the fraction of charged compound, the pKa 
value is obtained from the inflection point of the sigmoidal curve obtained when the retention 
time is plotted against the pH of the buffer. The CE approach is highly flexible, since different 
determination methods, such as spectroscopy or nitrogen detection, can be employed. 
Furthermore, it is compatible with high-throughput requirements and sample consumption is 
very low with about 0.2 ng per injection.10 Unlike in the previously described methods, 
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sample impurities usually do not influence the results, since CE is a separation technique. One 
drawback is the requirement of 50 µM solutions, which could cause problems with 
compounds of low solubility.  
 
Finally, in silico pKa prediction is fast and inexpensive. Nevertheless, commercial software 
needs to be validated and trained when applied to a new class of compounds.11 
 
Overall, pKa determinations depend on expensive, automated instrumentation or on laborious 
and time-consuming manual titration experiments. Furthermore, sample consumption is often 
critical. Since typically only milligram amounts of test compounds are available and the 
investment in expensive equipment is not justifiable for single pKa determinations, alternative 
approaches are still required.  
 
NMR offers an interesting alternative. Although specific approaches based on 15N-, 11B- or 
19F-NMR spectroscopy are reported,12-14 the pH-dependence of chemical shifts of 13C nuclei 
adjacent to ionizable functions is a more general approach for pKa determinations
15 and has 
successfully been employed for the determination of both pKas of acids
16-20 and bases.12,21 
Additionally, 13C-NMR spectroscopy (often in combination with 1H- or 15N-NMR) allows the 
determination of pKa values in isotopically enriched proteins. The applicability has been 
demonstrated with Bacillus circulans Xylanase22 or calmodulin.23 Furthermore, pH-
implications on structure24,25 and functionality26,27 can be investigated as well. However, 
without isotope enrichment, the low natural abundance of 13C nuclei (1.11%) results in 
prolonged measurement times, a substantial drawback of pKa-determination by 
13C-NMR 
spectroscopy. 
 
Beneficial effects, such as low sample consumption and short measurement times, which 
result from the higher abundance of 1H, lead to an improvement of sensitivity by a factor of 
320028 and favor pKa determination by 
1H-NMR. Various applications, i.e. pKa determination 
of amino acids,29 residues in peptides,30 and whole proteins such as human hemoglobin,31 
myoglobin,32 protein tyrosine phosphatase,33 thiosubtilisin,34 hen and turkey lysozymes,35 
human thioredoxin,36 and Myobacterium tuberculosis RecA intein37 have been reported. 
Moreover, the pKa values for single compounds
38,39 and for small, restricted datasets40-42 were 
also determined. Finally, the method can be used to determine the micro-speciation of 
compounds,43,44 i.e. the site-specific pKa values in multiprotic compounds that might overlap 
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and hence lead to only one measurable macro-pKa. It has been shown that micro-pKa values 
can have important implications on pharmacokinetic behavior.45 However, to our knowledge, 
the broad applicability of the method in drug discovery has not been demonstrated. We 
therefore explored scope and limitation of the 1H-NMR approach for pKa determination 
regarding measurement time and sample consumption.  
 
2. Material and methods 
 
Nuclear magnetic resonance spectroscopy was performed on a Bruker Avance III Ultra Shield 
at 500 MHz (1H-NMR) spectrometer. Chemical shifts are given in ppm. Presaturation 
experiments were performed in order to clearly see the diluted ligand without complications 
due to the larger H-O-D signal.46  
 
Deuterium oxide and deuterated d6-dimethyl sulfoxide were purchased from Armar 
Chemicals. Dimethyl sulfoxide, N-acetylneuraminic acid, diazepam, phenol, papaverin, 
propranolol, paracetamol, neocuproine, 5-nitro-1,10-phenanthroline, 4,7-dimethoxy-1,10-
phenanthroline, 4-phenylbutylamine, serotonin, benzoic acid, aniline, phenobarbital, 
diltiazem, promethazine, sucrose, and uracil were purchased from Sigma. Imidazole was 
purchased from Acros Organics. Dioxane was obtained from Fluka. 1,10-phenanthroline and 
2,2’-bipyridine were purchased from Riedel-de Haën. Codeine phosphate, acetylsalicylic acid, 
benzocaine, and phenazone were purchased from Siegfried AG. 4-Aminopyridine-2-
carboxylic acid was purchased from Apollo Scientific. 2-Amino-1,10-phenanthroline was 
purchased from Specs.  
 
For an optimal planning of the experiments, the software CS ChemBioDraw® Ultra (version 
11.0.1) was used to predict 1H-NMR spectra of the compounds in the various ionization 
states.  
 
For the measurement, a 10-4 M solution of the analyte in D2O was prepared (primary solution) 
and dioxane was added as an internal standard to obtain a 50 µM solution. When DMSO stock 
solutions were used, DMSO was used as internal standard. The primary solution was 
aliquoted into 8 to 15 samples and the pH values of the samples were adjusted (close to the 
predicted pKa, at the pKa itself, and at two extreme pH values, e.g. 1 and 13.5) with 0.5 M or 8 
M NaOH and 0.5 M or 4 M HCl, respectively. Aliquots (500 µl) of samples at each pH value 
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were transferred to NMR tubes and the recorded spectra were analyzed with the software 
MestReNova (Mestrelab research, version 5.2.5-4119). The resulting chemical shifts of a 
specific proton close to the ionizable function were plotted against the pH value resulting in a 
sigmoidal curve (software Prism®, GraphPad, version 5.0b). The pKa was determined from the 
inflection point (Figure 1). Alternatively, it was recently shown that Excel® can be used for 
the same purpose.47 Since the measurements were performed in D2O, 0.41 needs to be 
subtracted from the result to yield the values for a water environment.30 
  
 
Figure 1: Chemical shift dependence on the ionization state of the analyte paracetamol. When plotted against the 
corresponding pH values, the pKa value corresponds to the inflection point of the resulting sigmoidal curve. The 
downfield doublet is the resonance for the protons in meta-position to the hydroxy-moiety whereas the upfield 
one belongs to those in ortho-position.  
 
3. Results and discussion 
 
In previously reports, e.g.,15,29 pKa values were determined by measuring chemical shifts 
using typically more than 15, and only in some isolated cases, e.g.,39 9 data points. To 
determine an optimal compromise between data quality on the one and sample and time 
consumption on the other hand the number of data points was optimized. Table 1 shows that 9 
data points yield in general excellent results for pKa over eleven orders of magnitude (pKa 
values from 1.44 to 12.6). However, for compounds with extremely low or high pKa values 
such as uracil, the number of data points had to be increased, expanding the applicability 
range by almost another order of magnitude (pKas up to 13.3). 
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The 1H-NMR approach allows pKa determinations either with low sample consumption or 
short measurement time. For the first case, 50 µM solutions at 9 pH-values are usually 
sufficient. The approach is also of utility for compounds with low solubility. In addition, the 
required amount of a sample can be further reduced by using Shigemi NMR tubes, requiring 
as little as 200 µL per sample. When only very limited sample amounts are available, one 
sample with a progressional pH change is used. By this approach, as little as 6.25 µg of a 
compound with a molecular weight of 500 are required or even less (2.5 µg) when a Shigemi 
tube is used. As a consequence, the pKa value of compounds with a solubility of as little as 
12.5 ng/mL can still be assigned. Furthermore, since NMR is a non-destructive method, the 
analyte can be recovered provided no pH-dependent decomposition occurred. Finally, when a 
fast determination is required, samples with higher concentrations can be used. The overall 
measurement time is typically in the range of less than 5 minutes and thereby reduced by a 
factor of 10 compared to 13C-NMR spectroscopy.  
 
For the validation of the approach a homogeneous data set is required. When not indicated 
otherwise, the reference values obtained by electropotentiometry were therefore taken from 
one reference.10 For comparison, pKa-values for a small set of phenanthrolines were 
determined by UV spectrophotometry  (SGA) on a Sirius instrument. The results are in 
excellent agreement with both values obtained by 1H-NMR spectroscopy and by reference 
values of potentiometric titrations (Table 1). By contrast, in silico predictions of pKa-values 
calculated by EPIK48 show a much higher maximal deviation (3.83 pH-units) than 1H-NMR-
based results (0.51 pH-units).  
 
pKa values determined by 
1H-NMR differ typically by +/- 0.3 units from literature data (Table 
1). Only for five compounds these limits were exceeded, with a difference of maximally - 
0.48 to + 0.51. The reliability of the approach is also highlighted in Figure 2, which shows the 
excellent correlation to reference values over 12 orders of magnitude reflected by an R2 value 
of 0.99. 
 
A clear advantage of the NMR method is the possibility to start from a DMSO stock solution 
as usually prepared for biological testing. In this case, the DMSO peak (at 2.71 ppm)49 is used 
as internal standard. A possible disadvantage is the superposition of a resonance of interest of 
the test compound with the DMSO resonance. In contrast to earlier publications, e.g.,30 HCl 
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and NaOH can be used instead of DCl and NaOD for the adjustment of the pHs of the 
samples. The small amounts of added base or acid do not generate spectral disturbances when 
the H2O signal is suppressed, e.g..
29,42 
 
Table 1: pKa values obtained by NMR-spectroscopic and spectrophotometry compared to published data,
10 
unless indicated otherwise, with deviations. EPD: electropotentiometric determination, * deviation from 
spectrophotometrically determined values. 
Compound NMR 
pKa by 
spectro-
photometry  
published 
pKa (EPD)
10
 
Deviation from 
published pKa  
[pH units] 
Computed 
pKa 
(Epik)
48
 
Phenazone 0.94  1.44 0.5 4.92 
Benzocaine 2.45  2.39 -0.06 5.52 
Neuraminic acid 2.49  2.60 0.11 5.6 
Diazepam 3.07  3.35 0.28 3.88 
Acetyl salicylic acid 3.24  3.50 0.26 5.08 
Benzoic acid 4.02  3.98 -0.04 5.41 
Aniline 4.38  4.6050 0.22 4.5 
Papaverine 6.1  6.39 0.29 9.32 
Imidazol 6.95  6.9551 0 6.67 
Phenobarbital 7.26  7.49 0.23 6.64 
Codeine 8.15  8.22 0.07 9.42 
Diltiazem 8.5  8.02 -0.48 9.16 
Promethazine 9.21  9.00 -0.21 8.75 
Propranolol 9.38  9.53 0.15 9.09 
Paracetamol 9.84  9.63 -0.21 10.05 
Phenol 9.97  10.01 0.04 9.92 
4-Phenylbutylamine 10.53  10.50 -0.03 9.94 
Serotonin 10.92, 10.08  10.91, 9.97 -0.01, -0.11 9.84, 9.73 
Sucrose 12.93  12.60 -0.33 13.08 
Uracil 13.72, 9.34  13.28, 9.21 -0.44, -0.31 9.45, 9.1 
1,10-Phenanthroline 4.73 5.00 4.8052 0.27* 4.92 
2-Amino-1,10-phenanthroline 6.56 6.73  0.17 5.52 
4,7-Dimethoxy-1,10-phenanthroline 6.42 6.69  0.27 5.6 
5-Nitro-1,10-phenanthroline 3.15 3.66 3.5752 0.51* 3.88 
5-Amino-1,10-phenanthroline 5.37 5.57 5.7853 0.2* 5.08 
Neocuproin 5.63 5.74 6.1554 0.11* 5.41 
2,2-Bipyridine 4.54 4.54 4.4454 0* 4.5 
4-Aminopyridine-2-carboxylic acid 9.57, 1.01 9.43  -0.14 9.32, 0.78 
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Figure 2: Comparison of published data with values obtained by the presented 1H-NMR method. 
 
The presented 1H-NMR method is suited to obtain a reasonable estimate of pKa values rather 
than high-precision data. Therefore, spectra at merely 8 to 15 pH values per compound are 
recorded compared to the much higher number of data points required for other methods. 
Furthermore, the ionic strength of the solution was not considered and the determination in 
D2O is only a surrogate for the determination in H2O. Nevertheless, despite these constraints, 
accurate results, which are reproducible over time, were obtained.  
 
However, there are also some limitations with the presented method, e.g. when the chemical 
shift of protons adjacent to ionizable centers are not resolved. In these cases, other NMR 
methods, including 13C-, 15N- or 19F-NMR spectroscopy or 2D-methods, such as HSQC, can 
be applied. The latter approach allows to determine the protonation site, an information not 
always evident in other approaches. Furthermore, by the use of different solvents (e.g. 
deuterated methanol), the pKa values of sparsely soluble compounds can be determined. In 
those cases measurements have to be performed at different water/organic solvent ratios, to 
allow correction for the influence of the organic solvent on pKa, by applying e.g.Yasuda-
Shedlovsky extrapolations.55,56  
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4. Conclusion 
 
In conclusion, a 1H-NMR method was revisited, which allows a fast, sensitive and reliable 
determination of pKa values over a broad pH-range. In comparison to other methods, such as 
potentiometric titration or capillary electrophoresis, the sample consumption is low. In 
addition, since an NMR instrument is available in nearly every synthetic chemistry lab, 
investment in additional equipment is not necessary.    
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3 Results and discussion 
The PADMET-platform was used to determine pharmacokinetic properties of compounds 
from various research projects. A choice of results and their implications is presented in this 
chapter. 
 
3.1 Pharmacokinetic properties of FimH antagonists with biphenyl-moiety 
The aim of the FimH project is to find highly active and orally available antibiotics to treat 
urinary tract infections. The PADMET platform was used to identify compounds with 
promising properties concerning their absorption from the gastrointestinal tract and a fast 
renal excretion. 
 
Matthias Wittwer performed or supervised all experiments aimed at the determination of 
pharmacokinetic parameters and the interpretation of the results (except for the metabolic 
stability assay). Furthermore, he helped evaluating and interpreting the in vivo PK-
experiments and wrote the experimental part (together with S. Kleeb) as well as the discussion 
part concerning the experiments mentioned above. 
 
This work was published in the Journal of Medicinal Chemistry:  
 
Klein, T.*; Abgottspon, D.*; Wittwer, M.*; Rabbani, S.*; Herold, J.*; Jiang, X.; Kleeb, S.; 
Lüthi, C.; Scharenberg, M.; Bezençon, J.; Gubler, E.; Pang, L.; Smiesko, M.; Cutting, B.; 
Schwardt, O.; Ernst, B. FimH Antagonists for the Oral Treatment of Urinary Tract Infections: 
From Design and Synthesis to in Vitro and in Vivo Evaluation J. Med. Chem. 2010, 53, 8627-
8641. 
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3.2 Factors influencing the permeation properties of carbohydrate 
mimetics 
Carbohydrate mimetics are generally not expected to permeate through membranes by passive 
diffusion. Nevertheless, for several FimH antagonists promising PAMPA results were 
achieved and confirmed by in vivo PK-experiments, as described before. As a consequence, 
the parameters influencing the penetration of carbohydrate mimetics through a lipid bilayer by 
passive diffusion were explored. Various in silico descriptors and experimental logD7.4 values 
were thus tested regarding their capability of explaining PAMPA results. 
 
Matthias Wittwer performed or supervised all PAMPA and logD7.4 determinations and 
interpreted the results. The work on the manuscript was shared between the two equally 
contributing authors of this publication. 
 
This manuscript is in preparation for the Journal of Medicinal Chemistry. 
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Abstract 
 
Since the oral application of drugs is the most convenient way of therapy it is the aim of most 
drug discovery projects to identify orally available compounds. Besides metabolism and 
solubility problems, the crossing of the intestinal mucosa represents a major obstacle and 
properties related to good permeation are thus beneficial. Various assays have been developed 
to predict the uptake from the gastrointestinal tract, amongst them the parallel artificial 
membrane permeation assay (PAMPA). The special characteristics of this assay enable the 
determination of passive permeation without the influence of active transport processes. Even 
though the latter are important for distribution and uptake in various tissues and organs, they 
are suspected to play a small role for gastrointestinal absorption. 
 
Although the in silico prediction of oral bioavailability remains difficult, considerable success 
has been achieved regarding the prediction of passive membrane permeation. The descriptors 
involved in this process are generally well understood and readily accessible. Single or 
combined descriptor models (typically including molecular weight, calculated logP, number 
of hydrogen bond donors and acceptors or surface area descriptors) have been developed.  
 
While these concepts have been extensively utilized for peptides and marketed drugs, no 
studies examining the permeation behavior of carbohydrate mimetics have been released up to 
date. This work therefore focuses on the elucidation of factors influencing the passive 
permeation of such compounds. For this purpose, PAMPA as well as logD7.4 values were 
determined and in silico descriptors were calculated for a homologous set of 62 carbohydrate 
mimetics containing mannose. Calculated logP values as single descriptor proved to correlate 
best to PAMPA results of this data set. A combination of descriptors did not yield a better 
correlation. Interestingly, surface area descriptors that are commonly used for the prediction 
of permeation were much less correlated to PAMPA results than calculated logP values. 
Furthermore, calculated logP values were superior to experimental logD7.4 values. In 
conclusion, the results presented here suggest that the permeation behavior of carbohydrates is 
influenced primarily by lipophilicity and that other descriptors are less relevant. This is in 
contrast to previous findings for other compound classes. 
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1. Introduction 
 
The oral application of a drug is the most convenient way of therapy for patients. Therefore, 
whenever possible it is the aim of drug discovery projects to find orally available molecules 
for the treatment of diseases. Amongst other barriers such as metabolism and solubility 
problems, the crossing of the intestinal mucosa represents a major obstacle on the way of a 
drug to its target.1 Properties related to good permeation or factors enabling active 
transportation are thus essential and numerous assays have been developed to assess these 
parameters. For the determination of a compound’s ability to cross a membrane by passive 
diffusion, PAMPA (parallel artificial membrane permeation assay) has been introduced.2 The 
study of active transport processes and to a limited extent also metabolism is performed with 
cell-based assays using Caco-23 and MDCK4 cells. There is an ongoing debate on whether 
active transport processes play a role for oral absorption or if concentrations in the 
gastrointestinal tract after oral dosing are too high and thus transporters would be saturated.5, 6  
The in-silico prediction of oral bioavailability as a whole remains a difficult task within 
pharmacokinetic modeling.7, 8 Considerable success has been reached, though, concerning the 
prediction of transcellular permeation by passive diffusion.9 Different approaches have been 
used to identify descriptors that significantly correlate with good permeation.10 The simplest 
method for permeation prediction is the use of rules of thumb such as Lipinski’s Rule of 
Five11 or the Veber rules.12 Concerning prediction of passive permeation with artificial 
membranes, models based on a single descriptor such as H-bonding have been published.13 
Most publications, however, focus on models with combined descriptors that are either 
partially of experimental origin14 or purely computational(e.g. PSA and logP).15, 16 
Furthermore, QSAR models for the prediction of permeation have been developed,17-21 in one 
case even a bilinear QSAR model.22 Similar models were also described for permeation 
results based on Caco 2-assays23-27 or on intestinal permeability determinations in animals and 
humans.28-33 These models are usually similar to the ones derived from PAMPA results 
regarding the utilized descriptors, typically including molecular weight, calculated logP 
values, number of hydrogen-bond donors and acceptors, pKa values, number of rotatable 
bonds, or surface area descriptors.  
To our knowledge, no studies examining the permeation by passive diffusion of carbohydrate 
mimetics have been released up to date. A possible reason might be that carbohydrates and 
mimetics thereof are generally considered to be drug-unlike34 and that permeation is generally 
not expected for this class unless active transport processes can be exploited like in the 
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example of Valacyclovir.35 This does not hold true, as exemplified by compounds presented 
in a recently published paper and by compounds not yet published.36-38 In this study, we focus 
on the elucidation of important factors contributing to PAMPA permeation of carbohydrate 
mimetics by quantifying the predictive power of several molecular descriptors. Thereby, 
requirements for orally available carbohydrate mimetic drugs were identified. 
 
 
2. Materials and methods 
 
logD7.4 determination. The online in silico prediction tool Virtual Computational Chemistry 
Laboratory (VCCLAB)39, 40 was used to estimate the logP values of the compounds. 
Depending on these values, the compounds were classified into three categories: hydrophilic 
compounds (logP below zero), moderately lipophilic compounds (logP between zero and one) 
and lipophilic compounds (logP above one). For each category, two different ratios (volume 
of 1-octanol to volume of buffer) were defined as experimental parameters: 
 
Compound type logP Ratios (1-octanol: buffer) 
hydrophilic  < 0 30:140, 40:130 
moderately lipophilic 0 - 1 70:110, 110:70 
lipophilic > 1 3:180, 4:180 
 
Equal amounts of phosphate buffer (0.1 M, pH 7.4) and 1-octanol (Sigma-Aldrich, St. Louis 
MI, USA) were mixed and shaken vigorously for 5 min to saturate the phases. The mixture 
was left until separation of the two phases occurred, and the buffer was retrieved. Stock 
solutions of the test compounds were diluted with buffer to a concentration of 1 µM. For each 
compound, six determinations, i.e., three determinations per 1-octanol:buffer ratio, were 
performed in different wells of a 96-well plate. The respective volumes of buffer containing 
analyte (1 µM) were pipetted to the wells and covered by saturated 1-octanol according to the 
chosen volume ratio. The plate was sealed with aluminium foil, shaken (1350 rpm, 25 °C, 2 h) 
on a Heidoph Titramax 1000 plate-shaker (Heidolph Instruments GmbH & Co. KG, 
Schwabach, Germany) and centrifuged (2000 rpm, 25 °C, 5 min, 5804 R Eppendorf 
centrifuge, Hamburg, Germany). The aqueous phase was transferred to a 96-well plate for 
analysis by liquid chromatography-mass spectrometry (LC-MS).  
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logD7.4 was calculated from the 1-octanol:buffer ratio (o:b), the initial concentration of the 
analyte in buffer (1 µM), and the concentration of the analyte in buffer (cB) with equilibration:  
 
! 
logD7.4 =
1µM " c
B
c
B
#
1
o :b
 
 
The average of the three logD7.4 values per 1-octanol:buffer ratio was calculated. If the two 
mean values obtained for a compound did not differ by more than 0.1 unit, the results were 
accepted. 
 
PAMPA: The conditions for logPe determination with the PAMPA permeation assay were 
chosen according to the manufacturer’s recommendations due to the fact that calculated logP 
values were lower than two.41 For each compound, measurements were performed at three pH 
values (5.0, 6.2, 7.4) in quadruplicates. For this purpose, 12 wells of a deep well plate, i.e., 
four wells per pH-value, were filled with 650 µL System Solution (pIon, Woburn MA, USA, 
P/N 110151). Samples (150 µL) were withdrawn from each well to determine the blank 
spectra by UV-spectroscopy (SpectraMax 190, Molecular Devices, Silicon Valley Ca, USA). 
Then, analyte dissolved in DMSO was added to the remaining System Solution to yield 50 
µM solutions. To exclude precipitation, the optical density was measured at 650 nm, with 
0.01 being the threshold value. Solutions exceeding this threshold were filtrated. Afterwards, 
samples (150 µL) were withdrawn to determine the reference spectra. Further 200 µL were 
transferred to each well of the donor plate of the PAMPA sandwich (pIon, P/N 110 163). The 
filter membranes at the bottom of the acceptor plate were impregnated with 5 µL of GIT-0 
Lipid Solution (pIon, P/N 110669) and 200 µL of Acceptor Sink Buffer (pIon, P/N 110139) 
were filled into each acceptor well. The sandwich was assembled, placed in the GutBoxTM, 
and left undisturbed for 16 h. Then, it was disassembled and samples (150 µL) were 
transferred from each donor and acceptor well to UV-plates. Quantification was performed by 
both UV-spectroscopy and LC-MS. logPe-values were calculated based on LC-MS results 
with the aid of the PAMPA Explorer Software (pIon, version 3.5). For LC-MS 
determinations, the acceptor medium was diluted with acetonitrile at a 1:1  ratio (to break up 
the micelles) and each reference well was measured directly after the according donor well 
(leading to less variability). Furthermore, both donor and reference samples were diluted in 
order not to exceed the linear concentration range of triple quadrupole-MS instruments. 
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LC-MS measurements. Analyses were performed using a 1100/1200 Series HPLC System 
coupled to a 6410 Triple Quadrupole mass detector (Agilent Technologies, Inc., Santa Clara 
CA, USA) equipped with electrospray ionization. The system was controlled with the Agilent 
MassHunter Workstation Data Acquisition software (version B.01.04). The column used was 
an Atlantis® T3 C18 column (2.1 x 50 m) with a 3-µm particle size (Waters Corp., Milford 
MA, USA). The mobile phase consisted of two eluents: solvent A (H2O, containing 0.1% 
formic acid, v/v) and solvent B (acetonitrile, containing 0.1% formic acid, v/v), both delivered 
at 0.6 mL/min. The gradient was ramped from 95% A/5% B to 5% A/95% B over 1 min, and 
then hold at 5% A/95% B for 0.1 min. The system was then brought back to 95% A/5% B, 
resulting in a total duration of 4 min. MS parameters such as fragmentor voltage, collision 
energy, polarity were optimized individually for each drug, and the molecular ion was 
followed for each compound in the multiple reaction monitoring mode. The concentrations of 
the analytes were quantified by the Agilent Mass Hunter Quantitative Analysis software 
(version B.01.04). 
 
Molecular modeling: The main goal was to identify descriptors with the highest information 
content regarding the quantitative description of structure-property (permeation) relationship 
for a set of carbohydrate mimetics. Such descriptors could be used in the later development 
phases to rapidly identify drug candidates with decreased permeation. 
Each molecule was subjected to a thorough conformational analysis using the mixed 
torsional/low-mode sampling algorithm as implemented in the MacroModel software.42 The 
search for energetically accessible conformations was done using water and 1-octanol  
implicit solvation models in order to properly account for conformational differences in polar 
and organic solvent. In total, 2000 starting geometries were generated for each compound and 
minimized using a TNCG gradient method and an OPLS2005 force-field. Resulting 
conformations within an energy window of 2 kcal/mol were saved. On average, for a single 
compound this approach yielded ~70 conformers in water and ~60 in octanol. 
A large pool of various descriptors was calculated using the QikProp program by Schrodinger, 
LCC43 and the online version of the Dragon software (E-DRAGON) available within the 
VCCLAB.39 These descriptors were calculated taking only a single conformation into account 
– the global minimum in the case of the QikProp program and a pseudo-random geometry 
generated by the CORINA molecular builder as implemented in the VCCLAB in the case of 
the E-DRAGON software. 
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Special attention was paid to the evaluation of the descriptors which depend on the 3D 
structure of the molecule and are well known to significantly correlate with permeation, 
namely (polar) surface area and lipophilicity. Thus, besides the global minimum conformation 
(descriptor values denoted by the subscript index “global minimum”) as calculation basis, the 
values of these descriptors were calculated also based on several conformations within an 
energy window of 2 kcal/mol from the global minimum. The final values were adjusted by 
either the Boltzmann weighting algorithm (values denoted by the subscript index 
“Boltzmann”) or by simple averaging (denoted by “averaged”). In order to calculate the 
Boltzmann weighting factors, relative energies from molecular mechanics or quantum 
mechanics calculations were used. 
The lipophilicity coefficient logPOctanol/Water was calculated based on the solvation energies in 
the respective solvents using the following equation: 
 
logPOctanol/Water = (DGs Water – DGs Octanol) / 2.303 RT 
 
For each single conformer the solvation energies DGs Water and DGs Octanol were obtained from 
single point calculations using a SM5.42 solvation model,44 PM3 Hamiltonian and CM3 
charge model (ICMD=312, ICDS=12) as implemented in the GAMESS-Plus software.45 For 
comparison, the lipophilicity coefficients were additionally calculated using the ALOGPs 2.1 
program of the VCCLAB.39 
Surface area descriptors were calculated using an in-house program. First, the solvent 
accessible surface area (SASA) was calculated using the rolling sphere approach. Next, the 
solvent accessible surface was atom-mapped and the sum of areas assigned to oxygen and 
nitrogen atoms was calculated (polar surface area, PSA). 
 
 
3. Results and discussion 
 
The main interest of this study was to elucidate which factors influence the permeation 
properties of carbohydrate mimetics. Similar studies have been performed for other compound 
classes and various descriptors influencing passive permeation have been identified, most 
prominently for lipophilicity, molecular weight, surface area, and hydrogen bonding. PAMPA 
was used as reference assay since passive diffusion can be studied without disturbing 
influences of active transport processes.  
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All logPe and logD7.4 values presented here were determined in the same laboratory under the 
same conditions and thus represent a homogeneous data set. Three compounds were excluded 
due to their low solubility (thermodynamic solubility at pH 6.5 less than 1 µmol [33-35]), 
which could possibly interfere with assay results. This represents just a measure of precaution 
since normally precipitation is detected by UV-spectroscopy and the samples are filtered prior 
to PAMPA execution. Since no ionized compound (at assay pH values) showed any 
permeation (log Pe = -10), there was no need to calculate and consider pKa values.  
Furthermore, it is obviously of critical importance for the validity of the approach to correctly 
interpret the role that active transport processes might play for in vivo availability. For the 
biphenyl-compounds a comparison of PAMPA with Caco-2 results suggests a weak influence 
of active transportation for compounds with the carboxy-moiety while no such effect is seen 
for the respective esters that are permeating well in both assays.36 In a mouse in vivo model in 
the same publication no detectable appearance of the carboxy-compounds in plasma but low 
concentrations in the urine were observed. Contrastingly, a bioavailability of 10% was 
determined for the esterified compounds. Furthermore, the esterified compound showed a 
similar treatment efficacy in an infection study after p.o. application as the according carboxy-
compound after i.v. injection. These results, though only punctiform, suggest that PAMPA 
results of the carbohydrate mimetics presented in this study are relevant with respect to in vivo 
application, especially when combined with Caco-2 measurements. An in silico prediction 
approach thus bears the advantage of yielding relevant information at lower time 
consumption. Moreover, better understanding of the factors influencing permeation can be 
used for rational design approaches. 
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Table 1. Correlation of selected experimental and calculated descriptors with PAMPA permeation (logPe). 
Remark: nonPSA was calculated as SASA – PSA; fractionPSA was calculated as PSA/SASA. 
Descriptor r r
2 
 Descriptor r r
2 
0D - 2D    3D continued   
logPo/w QikProp 0.790 0.624  PSA global minimum -0.541 0.293 
# of HB acceptors QikProp -0.694 0.482  PSA averaged -0.525 0.276 
SASA QikProp 0.647 0.418  PSA Boltzmann -0.536 0.287 
Polarizability QikProp 0.614 0.377  SASA global minimum 0.563 0.317 
Volume QikProp 0.608 0.369  SASA averaged 0.539 0.291 
Globularity QikProp -0.592 0.350  SASA Boltzmann 0.542 0.293 
Molecular weight 0.485 0.235  Volume global minimum 0.429 0.184 
PSA QikProp -0.412 0.170  Volume averaged 0.467 0.218 
AC logP VCC Lab 0.894 0.800  Volume Boltzmann 0.461 0.213 
XLOGP3 VCC Lab 0.879 0.773  Globularity global minimum -0.558 0.312 
miLogP VCC Lab 0.877 0.769  Globularity averaged -0.583 0.340 
XLOGP2 VCC Lab 0.851 0.724  Globularity Boltzmann -0.573 0.329 
KOWWIN VCC Lab 0.848 0.719  nonPSA global minimum 0.768 0.590 
ALOGP VCC Lab 0.830 0.689  nonPSA averaged 0.757 0.573 
ALOGPs VCC Lab 0.791 0.626  nonPSA Boltzmann 0.760 0.578 
MLOGP VCC Lab 0.764 0.583  fractionPSA global minimum -0.776 0.603 
3D    fractionPSA averaged -0.768 0.590 
logPcalc. global minimum 0.849 0.721  fractionPSA Boltzmann -0.772 0.596 
logPcalc. averaged 0.887 0.787     
logPcalc. Boltzmann MM 0.895 0.800  experimental   
logPcalc. Boltzmann QM 0.921 0.848  logD7.4 0.802 0.642 
 
 
An overview of selected calculated descriptors and their correlation with the PAMPA 
permeation coefficient logPe is summarized in Table 1. The strongest predictors for good 
permeation were clearly lipophilicity descriptors. Interestingly, several calculated partitioning 
coefficients were better correlated with permeation behavior than experimentally measured 
distribution coefficients as reflected by their respective r2 values (e.g. logP calculated Bolztmann QM 
0.848 vs. logD7.4 0.642; Figure 1). This finding might be explained by the fact that the 
determination method for logD values used here is limited to a range between -1.5 to 4 thus 
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lacking an exact attribution for highly hydrophilic compounds. Indeed, the calculated results 
span over 6.25 units whereas the measured values cover only 4.5 units, so the extreme data 
points (positively) influencing the correlation are missing. Calculated logP values are well 
correlated with experimental logD7.4 values (r
2 = 0.753), although the calculated values are 
shifted towards the lower range and have a slightly steeper slope. This can be explained by the 
worse absolute accuracy of the solvation energies produced by the universal SM5.42 solvation 
model in case of the octanol. However, the description of the relative trends in solvation 
among the structures in the dataset remains very good. 
The quality of the calculated logP descriptors based on the 3D structures (and their respective 
solvation energies) largely depends on the final evaluation algorithm. If only the global 
minimum is taken into account, the approach produces values with a quality similar to pure 
fragment-based algorithms (logPcalc. global minimum r
2 = 0.721, average of all the correlation 
coefficients for logPs from the VCCLAB is 0.710). Simple averaging of the contributions 
from the low-energy conformers improves the correlation to r2 = 0.787 of logPcalc. averaged, 
while applying Boltzmann weighting leads to an even better correlation of  r2 = 0.800, which 
is just equal to the best fragment based method AC logP. When the Boltzmann weights are 
calculated based on the quantum-mechanical single point energies instead of molecular 
mechanics, the resulting correlation r2 reaches 0.848, which is the highest value of all 
descriptors. This confirms that a 3D-based approach might provide added value in terms of 
accuracy, if the contained information is extracted in a proper way. 
 
Figure 1. logPcalculated Boltzmann QM (left) and logD7.4 (right) plotted vs. logPe with the respective r
2 values. Empty 
squares represent the control group (see text). 
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Three groups can be distinguished when looking at the logPe vs. calculated logP correlation 
(Figure 1, left). The first group is composed of compounds that unambiguously permeate 
through membranes by passive diffusion (log Pe > -6, top right-hand corner), the second is 
represented by compounds with insufficient permeation properties (log Pe < - 7.5, bottom left-
hand corner), and the third group is situated in between. All three groups can be separated into 
clogP bins (> 0 for the first and <-2 for the second group) which emphasizes again the 
importance of this descriptor for passive permeation of the carbohydrate mimetics used in this 
study. 
The plots in Figure 1 represent just the best fit of a single descriptor to permeation values, i.e. 
no measure of reliability (such as a cross-validated r2) is explicitly given. Instead, compounds 
with no permeation (i.e. no measurable concentration is reached in the acceptor compartment 
after 16 hours) were used as control. When these compounds are plotted at the PAMPA 
threshold value (logPe = -10) against logPcalculated Boltzmann QM no false positive is observed 
(Figure 1, empty squares). 
In contrast to previously published studies, neither polar surface area (PSA) nor molecular 
weight, polarizability or descriptors of hydrogen bonding correlate strongly with permeation 
results. The rather low r2 values of PSA and the number of hydrogen bond acceptors as 
descriptors compared to calculated logP could be explained by the special chemical structure 
of the carbohydrate mimetics used in this study. The mannose moiety already contains 4 
hydrogen bond donors and 6 hydrogen bond acceptors and significantly contributes to a high 
PSA compared to other compound classes (PSA values observed in the current data set are 
between 100 Å2 and 177.5 100 Å2, the average is 131.5 Å2). As a comparison, the data set 
used by Veber containing 1117 compounds had an average PSA of 102.2 Å2.12 Therefore, for 
carbohydrate mimetics these descriptors might be less useful for the explanation of passive 
diffusion since they are less distinctive than for other classes. In the case of PSA, values 
calculated based on 3D structures showed a slightly increased correlation to permeation 
compared to those obtained from fragment-based summing. Nevertheless, they remain far 
from the predictive range (r2 values above 0.7). In contrast to this finding, the other 
descriptors (such as molecular volume, globularity or total solvent accessible surface area) 
showed even slightly lower correlations to permeation when calculated based on the 3D 
structures compared to their fragment-based analogs. Therefore, in these cases the increased 
computational costs would not be justified. 
Interestingly, the descriptors derived form PSA and SASA (solvent accessible surface area), 
namely the non-polar surface area (nonPSA) and the fraction of polar surface area 
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(fractionPSA, negative slope) showed some moderate correlation with permeation (r2 around 
0.590), indicating that the presence of lipophilic fragments compensating the rather high PSA 
of the mannose unit is indeed important for a successful transfer through the membrane layer. 
The lacking correlation between permeation and molecular weight might be explained by the 
homologous data set used in this study and consequently by the limited variability of this 
parameter (278.3 to 498.9, covering 220.6 units with a standard deviation of only 46.24). In 
the present dataset, there is no compound that would disqualify itself for passive permeation 
just based on the molecular weight when applying Lipinski’s Rule of Five.11 
None of the 1664 descriptors calculated with the software Dragon showed better correlation 
than the lipophilicity factors, which confirms the unique value of this descriptor for prediction 
of the passive permeation of the carbohydrate mimetics. Furthermore, it has the advantage to 
be easily comprehensible, intuitive, and facilely computable 
 
 
4. Conclusions 
 
In summary, clogP is the best descriptor for passive permeation of carbohydrate mimetics. A 
combination with other descriptors does not lead to a better correlation with PAMPA results 
thus emphasizing the importance of this single parameter for passive permeation of 
carbohydrate mimetics. This finding is remarkable since it differs from results of previously 
published studies with other compound classes. The results therefore suggest that the 
permeation behavior of carbohydrate mimetics is primarily influenced by lipophilicity and 
that other descriptors are less relevant. A possible explanation for this might be the high 
hydrophilicity of the mannose moiety that needs to be compensated in order to enable 
membrane permeation. 
Furthermore, the results can be used for the estimation of permeation within the restricted 
compound family of mannose derivatives similar to the ones used in this study. Compounds 
with logP values above 0, calculated according to the best methodology, are probably to 
exhibit high membrane permeation. On the other hand, compounds with values between -2 
and 0 might permeate to a limited extent and compounds with values below -2 cannot be 
expected to cross membranes. 
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3.3 Pharmacokinetic behavior of MAG antagonists 
MAG antagonists are used to treat central nervous lesions and are generally applied directly at 
the site of action, i.e., they are injected intrathecally. A compound’s stability in cerebrospinal 
fluid and the maintenance of a sufficiently high concentration in this compartment are critical 
parameters that were addressed by the means of the PADMET platform. 
 
The author determined the stability in artificial cerebrospinal fluid, the logD7.3 values, and the 
permeation through an artificial blood-brain barrier of all compounds and interpreted the 
results. 
 
This work was published in the Journal of Medicinal Chemistry:  
 
Mesch, S.; Moser, D.; Strasser, D. S.; Kelm, A.; Cutting, B.; Rossato, G.; Vedani, A.; 
Koliwer-Brandl, H.; Wittwer, M.; Rabbani, S.; Schwardt, O.; Kelm, S.; Ernst, B. Low 
Molecular Weight Antagonists of the Myelin-Associated Glycoprotein: Synthesis, Docking, 
and Biological Evaluation J. Med. Chem. 2010, 53, 1597-1615. 
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4 Summary and outlook 
During the past decades, pharmacokinetic characterization has been increasingly implemented 
already at early stages of the drug discovery and development process. Even though the study 
that sparked this development has been shown to be biased by a high percentage of 
antibiotics,2 the importance of such assays in avoiding preventable attritions has been 
recognized.107 As a result, a wealth of new assays has been developed and the existing 
procedures were continuously adapted to high-troughput requirements thus yielding a plethora 
of pharmacokinetic information.6 This provides project teams already at early stages with a 
basis for informed decisions and enables them to continue the development of the most 
promising compounds while abandoning less promising, especially pharmacokinetically 
questionable molecules. 
 
During this doctoral thesis, various assays have been established to determine 
pharmacokinetic properties of carbohydrate mimetics. Regarding their physicochemical 
properties, procedures to determine logD7.4, pKa, and solubility have been implemented. 
Furthermore, absorption is assessed by PAMPA and Caco-2 experiments and plasma protein 
binding is measured. These assays were combined to form the PADMET platform, with 
PADMET standing for physicochemical properties, absorption, distribution, metabolism, 
elimination, and toxicity. The rationale behind the platform was the elucidation of the 
pharmacokinetic behavior of carbohydrates and mimetics thereof as well as the development 
of compounds with ameliorated drug-likeness. 
 
During the development of the PADMET platform the need for a fast and simple pKa 
determination method became apparent. NMR spectroscopy offers an inexpensive, 
uncomplicated, and relatively fast approach that does not require special instrumentation. 
Furthermore, by the use of 1H-NMR spectroscopy both sample consumption and measuring 
time are drastically reduced. Additional advantages include the possible use of DMSO stock 
solutions as starting point and information about the site of protonation in multiprotic 
compounds. In brief, the assay is performed by gradually changing the pH of a sample 
solution and monitoring the chemical shift of protons adjacent to ionizable centers by 1H-
NMR spectroscopy. The shift is then plotted against the pH of the respective sample and the 
pKa is read out from the inflection point of the resulting sigmoidal curve. Even though this 
approach has been used before, the scope and limitations of it were never extensively studied. 
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Therefore, a methodology was developed and validated with a diverse set of compounds with 
pKa values between 1 and 14. Indeed, excellent correlations to literature values stemming 
from electropotentiometric titration and to values determined by spectral gradient analysis 
(UV-based) methods could be observed. Furthermore, pKa values determined by the 
1H-NMR 
methodology were closer to reference values compared to calculated values. 
 
To date, 93 carbohydrate mimetics have been characterized concerning their pharmacokinetic 
behavior. Thereof, 62 compounds were FimH antagonists for which PAMPA, logD7.4, pKa, 
and solubility values were determined. Additionally, permeation in the Caco-2 assay, plasma 
protein binding, and critical micelle concentration were measured for selected compounds. 
The remaining 31 carbohydrate mimetics consist of 16 selectine antagonists, 11 MAG 
antagonists, and 4 CD 22 antagonists of which only the MAG antagonists were further 
discussed in this thesis. Additional publications in the near future will reveal the 
corresponding pharmacokinetic properties of the other two compound classes. 
 
From the pharmacokinetic point of view, the aim of the FimH antagonist program was to 
develop orally available compounds with fast renal excretion. For this purpose, the 
components of the PADMET platform were used in order to predict the expected 
pharmacokinetic behavior and to select the most suitable compounds for in vivo testing. The 
desired profile included permeation in the PAMPA, suggesting oral bioavailability, and at the 
same time low logD7.4 values, sufficient solubility as well as low plasma protein binding, 
leading to fast renal excretion. Since compounds with low lipophilicity that are concomitantly 
permeating through membranes by passive diffusion are rarely achievable, a prodrug 
approach was chosen. Indeed, this allowed the synthesis of compounds that fulfilled the 
desired criteria. Finally, the predicted behavior based on in vitro results could be confirmed by 
in vivo studies in a UTI mouse model which highlights the usefulness of early 
pharmacokinetic assays. This strategy led to the first and up to date only orally available 
FimH antagonist. 
 
Both PAMPA and logD7.4 values of the FimH antagonist dataset were used for a thorough 
analysis of the underlying causes for membrane permeation of carbohydrate mimetics. For 
this purpose experimental and computational parameters were tested for their predictive 
power regarding passive membrane permeation of this compound class. To the best of our 
knowledge, it is the first time that such a study has been performed with carbohydrate 
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mimetics. Interestingly, the results of this study suggest that calculated logP values are the 
best descriptor for passive permeation of this compound class and other descriptors for 
surface area, polarizability or hydrogen bonding are less important. Furthermore, calculated 
logP values were more suited to explain the permeation behavior than experimental logD7.4 
values. Finally, a combination of descriptors did not markedly improve the predictive power 
compared to calculated logP as single descriptor. These findings are in contrast to previously 
published studies with other compound classes where combinations of descriptors yielded 
better prediction of permeation behavior than single descriptor models. In conclusion, the 
permeation behavior of carbohydrate mimetics is probably differing from other compound 
classes. 
 
For the MAG project the requirements for antagonists were defined differently. Oral 
availability was not required, since the compounds are planned to be injected directly to the 
site of action, i.e., the central nervous system (CNS). Instead, maintenance of a sufficiently 
high local concentration is critical and therefore permeation through the blood-brain barrier 
and degradation in the cerebrospinal fluid (CSF) were studied. For these purposes, a blood 
brain-barrier PAMPA was performed and the stability of the compounds was assessed in 
artificial cerebrospinal fluid. Neither permeation nor degradation were observed, thus yielding 
the desired properties. Therefore, the local concentration is probably maintained over a 
sufficiently long time period unless the compounds are removed during physiological CSF 
turnover processes. Nevertheless, active efflux (e.g., by P-gp) and unspecific binding to CNS 
tissue remains to be determined to draw final conclusions. 
 
The platform will be expanded in the near future. Assays for metabolic stability questions will 
be established by Simon Kleeb. A first step into this direction has been taken by building up 
an assay for the determination of ester cleavage, as exemplified in the FimH publication. 
Further developments will include the introduction of metabolic stability assays with 
microsomes (oxidative metabolism by cytochromes) and deepened understanding of 
glucuronidation. Moreover, the identification of metabolic soft spots in order to introduce 
stabilizing moieties and decrease metabolic degradation will be an important task. 
Additionally, more needs to be learned about the toxicity of the carbohydrate mimetics. 
Especially the incorporation of the Ames test196 or the GADD45a-GFP102 (human cells) 
genotoxicity assay into the PADMET platform seems promising. Furthermore, cytotoxicity 
assays, such as the MTT assay,103 should be established to enrich the early-toxicity profiling. 
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